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One Sentence Summary: Fetal lung regeneration via administration of extracellular vesicles 






Fetal lung underdevelopment, also known as pulmonary hypoplasia, is characterized by 
decreased lung growth and maturation. The most common birth defect found in babies with 
pulmonary hypoplasia is congenital diaphragmatic hernia (CDH). Despite research and clinical 
advances, CDH babies still have high morbidity and mortality rates, which are directly related to 
the severity of lung underdevelopment. To date, there is no effective treatment that promotes 
fetal lung growth and maturation. Herein, we describe a stem cell-based approach that enhances 
fetal lung development via the administration of extracellular vesicles (EVs) derived from 
amniotic fluid stem cells (AFSCs). Using fetal rodent models of pulmonary hypoplasia (primary 
epithelial cells, organoids, explants, and in vivo), we demonstrated that AFSC-EV administration 
promotes branching morphogenesis and alveolarization, rescues tissue homeostasis, and 
stimulates epithelial cell and fibroblast differentiation. We confirmed this regenerative ability in 
human models of lung injury, where human AFSC-EVs obtained following good manufacturing 
practices restored pulmonary epithelial homeostasis. Investigating EV mechanism of action by 
tracking AFSC-EV cargo transfer, profiling EV protein and RNA content, and sequencing target 
lung epithelial cells, we found that AFSC-EV beneficial effects were exerted via the release of 
RNA cargo. Particularly, miRNAs that regulate the expression of genes involved in lung 
development, such as the miR17~92 cluster and its paralogues, were highly enriched in AFSC-
EVs and were increased in AFSC-EV-treated primary lung epithelial cells compared to untreated 
cells. Our findings suggest that AFSC-EVs hold regenerative ability for underdeveloped fetal 





Fetal lung development is a crucial step during embryogenesis, which if disrupted leads to a 
condition called pulmonary hypoplasia. Hypoplastic lungs have fewer bronchiolar divisions, 
enlarged airspaces, defective alveolarization, and impaired tissue maturation (1). Pulmonary 
hypoplasia is idiopathic or secondary to associated malformations, the most common of which is 
congenital diaphragmatic hernia (CDH) (1, 2). CDH is a birth defect characterized by an 
incomplete closure of the diaphragm and herniation of intra-abdominal organs into the chest (1, 
2). Pulmonary hypoplasia secondary to CDH has a mortality rate of 40% with most babies dying 
within the first days of life (3), and with 60% of survivors suffering from long-term morbidities 
(4, 5). There is an unmet clinical need for an effective treatment that rescues lung growth and 
maturation, but none of the therapies tested to date has been successful (6). As pulmonary 
hypoplasia can be diagnosed as early as at the anatomy scan (18-20 weeks of gestational age), 
the paradigm of treatment in the last decades has focused on promoting lung growth and 
maturation before birth (6).  
Lung development is a complex process regulated by a network of signaling molecules. 
Particularly, some miRNAs control branching morphogenesis and epithelial and mesenchymal 
differentiation (7-9), and are missing or dysregulated in human and animal hypoplastic lungs 
(10-13). Correcting the dysregulated network of signaling molecules would be beneficial to 
promote lung regeneration in fetuses with pulmonary hypoplasia. 
A promising strategy to deliver a heterogeneous population of small RNA species is by 
administering extracellular vesicles (EVs) (14-16). EVs are biological membrane-bound 
nanoparticles carrying genetic material and bioactive proteins as cargo (17-19). EVs are key 




22). Amniotic fluid stem cells (AFSCs) could be the ideal source of EVs to promote lung 
regeneration as AFSCs integrate and differentiate into epithelial lung lineages (23), reduce lung 
fibrosis (24), repair damaged alveolar epithelial cells (25), and promote lung growth in a model 
of pulmonary hypoplasia secondary to CDH (26, 27). AFSCs confer regenerative ability despite 
low engraftment rates, thus suggesting a paracrine effect (26-28), which could be partly mediated 
by EVs. Recently, AFSC-EVs have been reported to hold regenerative potential in several 
animal models, including lung, kidney, and muscle injury (29). 
In the present study, we investigated whether AFSC-EV administration to various models of 
pulmonary hypoplasia could promote growth and maturation of underdeveloped fetal lungs.  
Results  
Rat AFSC-EV administration promotes growth and maturation in fetal hypoplastic lungs 
The most robust model of pulmonary hypoplasia relies on nitrofen administration to pregnant 
rats at embryonic day (E) 9.5 (30, 31), which mainly targets retinoic acid synthesis (32). In this 
model, the whole litter has a degree of lung underdevelopment analogous to that of human 
fetuses (2, 30-33). In utero nitrofen exposure results in fewer bronchiolar divisions and airspaces 
compared to lungs from uninjured fetuses (Fig. 1, A to C) (30). Administration of rat AFSC-EVs 
(rAFSC-EVs, mean size 140±5 nm) to hypoplastic lung explants harvested during the 
pseudoglandular stage (E14.5) resulted in improved branching morphogenesis (Fig. 1, A to C, 
fig. S1). Particularly, rAFSC-EV-treated lung explants had increased bud count and surface area 
compared to untreated hypoplastic lung explants and similar to control. This effect was 
specifically due to rAFSC-EVs, as administration of rAFSC conditioned medium (CM) or EV-
depleted rAFSC-CM did not rescue impaired terminal branching. As larger rAFSC-EVs (363±17 




we used small rAFSC-EVs (140±5 nm). We also tested whether the effects obtained with 
rAFSC-EVs could be replicated by another EV source, namely mesenchymal stromal cells 
(MSCs). There is growing evidence that MSC-EVs ameliorate bronchopulmonary dysplasia 
(BPD) (34), a neonatal lung condition similar to pulmonary hypoplasia secondary to CDH. 
However, rMSC-EV administration to hypoplastic lung explants did not rescue branching 
morphogenesis (Fig. 1, A to C, fig. S1). Moreover, rAFSC-EVs did not affect branching 
morphogenesis in uninjured control lungs (fig. S2, A and B). Investigating pathways responsible 
for branching morphogenesis, we observed that compared to control, hypoplastic lungs had 
lower expression of Fgf10, Vegfα and receptors (Flt1, Kdr), which were increased upon rAFSC-
EV administration (Fig. 1D) (35, 36).  
Along with compromised fetal lung growth, pulmonary hypoplasia is characterized by impaired 
maturation, a feature replicated with in utero nitrofen exposure (2, 30). Hypoplastic lungs have 
decreased cell proliferation and delayed epithelial cell differentiation, as demonstrated by 
increased density of distal progenitor cells (SOX9+) and reduced surfactant protein C (SPC) 
expression (Fig. 1, E to L, fig. S3, A and B) (32, 37, 38). rAFSC-EV administration rescued cell 
proliferation and improved epithelial cell differentiation, as evidenced by lower SOX9+ cell 
density (Fig 1, E and F) and increased SPC expression (Fig. 1, E to L). As reported, hypoplastic 
lungs had similar degree of apoptosis compared to control, and rAFSC-EV administration did not 
alter this phenotype (Fig. 1, M and N, fig. S3C) (33, 39). 
rAFSC-EV administration rescues homeostasis and stimulates differentiation of lung epithelial 
cells 
A hallmark of pulmonary hypoplasia secondary to CDH is impaired respiratory epithelial 




hypoplastic lungs of nitrofen-injured fetuses increased proliferation and reduced cell death back 
to control (Fig. 2, A and B). We confirmed that these effects were specific to rAFSC-EVs, as 
they were not reproduced by the administration of either rAFSC-CM, or EV-depleted rAFSC-
CM. Interestingly, rMSC-EVs improved proliferation of primary lung epithelial cells, but failed 
to rescue cell death (fig. S3, D and E). We also observed that rAFSC-EV administration to 
uninjured control cells did not change proliferation or cell death rates (fig. S2, C and D). 
To study rAFSC-EV effects on respiratory epithelial cell differentiation, we generated fetal lung 
organoids from nitrofen-injured and control lungs (Fig. 2C, fig. S3F). rAFSC-EV administration 
to nitrofen-injured organoids had proliferation rates similar to control organoids and higher than 
untreated nitrofen-injured organoids (Fig. 2D, fig. S3G). Moreover, rAFSC-EV administration 
improved respiratory epithelial differentiation, with higher SPC (marker of early distal 
epithelium and alveolar type II cells) and CC10 (marker of club cells) expression (Fig. 2, E and 
F, fig. S3, H and I).  
rAFSC-EV cargo content and its effect on lung epithelium 
rAFSC-EV effects on nitrofen-injured hypoplastic lungs and respiratory epithelium were 
associated with transfer of EV cargo, detected throughout the lung parenchyma (Movie S1) and 
primary lung epithelial cells (Fig. 3, A and B; Movie S2, S3). To study the cargo content, we 
differentially analyzed rAFSC-EV and rMSC-EV protein and RNA, as we had observed different 
effects between the two EV sources. Proteomics analysis identified 222 differentially expressed 
proteins, none of which had obvious molecular functions directly related to fetal lung 
development (fig. S4A). rAFSC-EVs contained proteins involved in EV formation (HSPa and 




To test whether rAFSC-EV effects were due to their RNA cargo, we treated rAFSC-EVs with 
RNase-A. We verified that RNase-A was captured by rAFSC-EVs and degraded their RNA 
cargo (Fig. 3, C to I). RNase-pretreated rAFSC-EVs administered to hypoplastic lung explants or 
primary epithelial cells derived from hypoplastic lungs did not rescue branching morphogenesis 
or epithelial homeostasis (Fig. 3, J to M). We confirmed that these effects were not due to carry-
over of RNase-A to the epithelial cells (fig. S4B). Taken together, these data suggested that the 
rAFSC-EV RNA was key for their biological effects on fetal lung development. With RNA-
sequencing we found that both rAFSC-EV and rMSC-EV cargos contained mRNA, tRNA, 
miRNA, and piRNA (Fig. 3N, fig. S4C). Among all, miRNAs were the RNA species most 
proportionally different between rAFSC-EV and rMSC-EV cargos. Compared to rMSC-EVs, 
rAFSC-EVs were enriched for miRNAs critical for lung development, such as the miR17~92 
cluster and paralogues (miRs-93, -106, -250, -363; fold enrichment range: 5.1 - 9.36; table S2, 
Fig. 3O). Moreover, rAFSC-EVs contained miRNAs that were reported to be dysregulated in 
hypoplastic lungs, such as miR-33 and miR-200 (table S3) (10, 12).   
To identify the regulatory pathways affected by rAFSC-EVs, we used mRNA-sequencing to 
compare gene expression between primary lung epithelial cells from nitrofen-injured lungs 
treated with rAFSC-EVs or rMSC-EVs. Nitrofen-injury altered the gene expression profile of 
primary lung epithelial cells compared to uninjured epithelial cells (fig. S4D). Gene set 
enrichment analysis showed that rAFSC-EV administration to nitrofen-injured primary epithelial 
cells altered the expression of genes related to epithelial differentiation and homeostasis 
maintenance, whereas rMSC-EV administration altered the expression of genes involved with 
cell cycle regulation and nuclear organization (Fig. 4, A and B, fig. S5, A and B). Furthermore, 




S4). We then asked if the miRNAs identified in the rAFSC-EV cargo were part of predicted 
regulatory networks with the mRNAs that were down-regulated in the target epithelial cells (Fig. 
4C). The network that resulted from this analysis showed that there were genes important for 
lung development and that were regulated by miR17~92 cluster and paralogues. Small RNA-
sequencing of nitrofen-injured rAFSC-EV-treated primary epithelial lung cells showed that most 
miRNAs in the network had higher expression compared to nitrofen-injured untreated cells (Fig. 
4C). Lastly, we correlated the miRNA cargo content with the miRNA target cell content, and 
their validated mRNAs in the target cells (fig. S6). This triple analysis identified miRNA-
mRNAs pairs that might be responsible for the phenotype observed and provided indirect 
evidence that the rAFSC-EV miRNA cargo was transferred to the target cells. 
Towards clinical translation of AFSC-EVs as treatment for fetal lung regeneration  
To test the effects of rAFSC-EVs in vivo, we used a surgical model of pulmonary hypoplasia 
secondary to CDH in fetal rabbits, as it allowed us to topically deliver our treatment (Fig. 5A) 
(41). To prevent rAFSC-EV egression, we performed tracheal occlusion on rabbit fetuses (Movie 
S4), a procedure currently used in clinical trials for selected CDH human fetuses (42). rAFSC-
EV administration improved lung alveolarization by increasing the number of alveoli, decreasing 
the alveolar wall thickness, and promoting alveolar lipofibroblast maturation (Fig. 5, B to E). 
Moreover, only rAFSC-EV-treated lungs had improved BMP signaling (BMP2, BMP4, Id1), 
important for alveolar maturation (Fig. 5F). These effects were not observed in rMSC-EV-treated 
lungs (fig. S5, C to E). 
To investigate whether rAFSC-EV beneficial effects could be translated onto human lung tissue, 
we obtained human AFSCs (hAFSCs) from donated amniotic fluid following clinically 




replicated similar effects on cellular homeostasis observed in rat models on both a validated 
model of lung injury with nitrofen-injured human alveolar epithelial (A549) cells and on 
nitrofen-injured primary human pulmonary alveolar epithelial cells (HPAEpiC) isolated from a 
fetus at 21 weeks of gestation (Fig. 5, G to J). We verified that fluorescently labeled PKH26+ 
hAFSC-EVs entered A549 cells and HPAEpiC (Fig. 5, K and L). Administration of human 
MSC-EVs (hMSC-EVs) to HPAEpiC did not rescue cell homeostasis, despite entering the cells 
(fig. S7, A to C). Lastly, when we tested hAFSC-EVs on the in vivo rabbit model, we found 
similar effects on alveolar wall thickness, as found with rAFSC-EV administration (fig. S7, D to 
F).  
Discussion 
In this study, we have shown that AFSC-EV administration to various models of pulmonary 
hypoplasia promotes fetal lung regeneration. Specifically, AFSC-EVs administered to fetal 
hypoplastic lungs rescued branching morphogenesis and alveolarization, promoted epithelial and 
mesenchymal tissue maturation, and re-established cellular homeostasis (Fig. 6). These 
beneficial effects were obtained through AFSC-EV RNA cargo, including miRNAs that regulate 
lung development.  
EVs are emerging as a successful strategy to promote tissue regeneration in various models. The 
regenerative potential observed in our models of fetal pulmonary hypoplasia has been reported in 
other models of tissue regeneration using either AFSC-EVs (29) or EVs from other stem cell 
sources (14-16, 20, 43, 44). In fact, there is increasing evidence that EVs secreted by stem cells 
carry cargo that stimulates stem cell-like paracrine functions on target cells such as renewal, 
differentiation, and maturation (45-47). In this study, we confirmed that rAFSC-EVs have 




cells, rAFSCs (fig. S8, A to D). For this reason and their immunological innocuity, EVs are an 
advantageous and safer cell-free alternative to stem cell-based therapies (48-50). Although GMP-
grade CM could be therapeutic in humans (51-53), in our study the EV fraction of the CM was 
more potent than the whole CM or than the EV-depleted CM fraction, as also observed by others 
(54, 55). This could be due to EVs carrying active molecules that are more concentrated than in 
parent cells (fig. S8E). This is in line with our previous findings that AFSC-EV concentration is 
the most important parameter responsible for their regenerative potential (29). Likewise, in the 
present study, we have shown that rAFSC-EV effects are dependent on the concentration of EVs 
isolated from CM, as well as on the size of the vesicles that enter target cells (fig. S1, D to G, 
Movie S2, S3, and S5). How size contributes to biological function of EVs remains unknown 
(56). Nonetheless, small EVs, also called exosomes (17), have traditionally been considered the 
EV subpopulation with more potent, protective, and pathological functions than larger vesicles, 
and therefore with more potential as diagnostic or therapeutic tools (29).  
We used MSCs as an alternative EV source, since MSCs are being tested in several clinical trials 
for BPD treatment (57), the lung condition that is most comparable to pulmonary hypoplasia. In 
our study, MSC-EV administration to pulmonary hypoplasia models did not have similar 
beneficial effects as AFSC-EV administration, despite entering primary lung cells (fig. S2, S3, 
Movie S6). The different effects obtained with the two EV populations may be due to differences 
in disease pathogenesis, where pulmonary hypoplasia is mainly the result of abnormal and 
delayed lung development, and BPD is a chronic postnatal lung disease with severe 
inflammatory response (58). Moreover, our analysis of the EV cargo identified profile 





In our models of pulmonary hypoplasia, we identified that rAFSC-EV RNA cargo was key to 
regenerate hypoplastic fetal lungs. This finding is in line with reports that EV-mediated effects 
occur through RNA transfer (14-17). When considering the rAFSC-EV specific genes in the 
context of miRNA cargo enriched in rAFSC-EVs, we found miRNA species important for the 
phenotypes observed, including branching morphogenesis, alveolarization, cell homeostasis and 
differentiation (table S2). Specifically, a family of miRNAs that is enriched in rAFSC-EVs 
compared to rMSC-EVs is the miRNA 17~92 cluster. This cluster is essential for lung branching 
morphogenesis (59), and when knocked out causes severe fetal pulmonary hypoplasia, making 
this a candidate mechanism that warrants further investigation (9). Moreover, small RNA 
sequencing analysis revealed that members of this cluster were up-regulated in rAFSC-EV-
treated nitrofen-injured primary lung epithelial cells (fig. S8F).  
Improved fetal lung development was observed not just when the same species of AFSC-EVs 
was administered on the same species of target cells (i.e. rAFSC-EVs on rat lung tissue or 
hAFSC-EVs on human lung epithelial cells), but also when we tested rAFSC-EVs or hAFSC-
EVs on the in vivo rabbit model (Fig. 5, A to F, fig. S7, D to F). We speculate that the 
improvement in alveolarization observed in rabbit fetuses is because some miRNAs and their 
targets are conserved across species (60). For instance, from the top 50 miRNAs that were 
enriched in hAFSC-EVs, 13 were evolutionarily conserved between human and rabbit species, 
including one member of the miR17~92 cluster member (table S5).  
Our study provides insights into the potential use of AFSC-EVs as a therapy for fetal pulmonary 
hypoplasia. Using GMP-grade hAFSC-EVs, we have confirmed similar beneficial effects on 
damaged epithelial cells derived from a fetal lung at the gestational age when pulmonary 




as a therapy in human fetuses, such as identifying the most effective and safest administration 
route. In this study, we employed topical administration via intra-tracheal injection in rabbit 
fetuses. This route could be further explored, also in clinical settings, as it is currently used to 
occlude the trachea of human fetuses with severe pulmonary hypoplasia secondary to CDH (42).  
We acknowledge that our study has some limitations. Our findings are mainly based on the use 
of animal models and human lung epithelial cells to study a complex human condition with an 
unknown etiology. However, obtaining human lung tissues from babies with pulmonary 
hypoplasia is not considered ethically acceptable nor has it been reported. Moreover, in this 
study we mainly focused on fetal lung epithelium and mesenchyme, but we did not examine 
other lung compartments such as pulmonary vasculature, which is known to undergo remodeling 
in hypoplastic lungs. Nonetheless, we observed improvements in pathways important for lung 
vascular development, such as VEGF and FGF10 that suggest the opportunity for further studies. 
Another limitation is that little is known about factors that alter lung development and the 
mechanisms that are dysregulated in pulmonary hypoplasia. Similarly, it remains unknown how 
exactly the EV RNA cargo species function. It is hoped that our transcriptomic profiling of both 
hypoplastic lungs and EVs increases the understanding on the pathogenesis of pulmonary 






Materials and Methods 
Study Design 
This study aimed to evaluate the ability of AFSC-EV administration to promote fetal lung 
growth and maturation in pulmonary hypoplasia. As obtaining human lung tissues from babies 
with CDH is not considered ethically acceptable, part of this study was conducted using animal 
models that closely resemble the degree of pulmonary hypoplasia observed in human fetuses. To 
advance towards a translational therapy, we obtained EVs from GMP-grade hAFSCs isolated 
from donated amniotic fluid during amniocentesis. We tested hAFSC-EVs first on a validated 
lung injury model using A549 alveolar epithelial cells (29, 61). To more closely replicate human 
fetal pulmonary hypoplasia, we investigated the GMP-grade hAFSC-EV effects on nitrofen-
injured human pulmonary alveolar epithelial cells obtained from a healthy fetus at 21-weeks of 
gestation. Experimental models and sample collections were approved by appropriate regulatory 
committees at: The Hospital for Sick Children, Toronto (protocol #39168 and 49892); University 
College London Hospital, London, UK (UCL/UCLH Joint Committee for the Ethics of Human 
Research, REC Reference: 08/0304); Ribeirão Preto Medical School, University of São Paulo, 
Brazil (191/2018+40/2020). Sprague-Dawley rats and New Zealand rabbits were used for animal 
studies. Samples from all models were randomly assigned to treatment groups. All data including 
outliers are shown, and all experiments were performed in at least triplicate, with the number of 
replicates indicated in the figure legends. Analysis of data was conducted by at least two blinded 
investigators. Additional details on methods used are provided in Supplementary Materials.  
Extracellular vesicles 
EVs from rat and human AFSCs or bone-marrow MSCs were isolated by ultracentrifugation 




(29). Based on previous studies, we established that 4x106 AFSCs cultured under these 
conditions secrete approximately 3x109±1x107 EVs, quantified by nanoparticle tracking analysis 
(29). For all experiments, EV doses are described as v/v (EV volume in CM volume). In 
accordance with the International Society for Extracellular Vesicles guidelines, EVs were 
characterized for size (nanoparticle tracking analysis), morphology (transmission electron 
microscopy), and expression of canonical EV-related protein markers (Western blot analysis), as 
described (29). To track EV migration into primary lung epithelial cells and lung explants, EV 
cargoes were fluorescently labelled for RNA and protein using Exo-Glow™ and for lipid 
membrane using PKH26. To determine the role of RNA in rescuing pulmonary hypoplasia, 
RNase enzymatic digestion of rAFSC-EV cargo was conducted and confirmed by bioanalyzer 
and immuno-electron microscopy.  
Experimental models of pulmonary hypoplasia 
Ex vivo - In fetal rats, pulmonary hypoplasia was induced as described (30, 40) with nitrofen 
administration to dams (100 mg) by oral gavage on E9.5. At E14.5, the dam was euthanized, and 
fetal lungs were micro-dissected. Lungs were grown on nanofilter membranes, and incubated for 
72 h in culture medium alone, rAFSC-CM, or medium supplemented with rAFSC-EVs or rMSC-
EVs (0.5% v/v). Fetal lungs from dams that received olive oil (no nitrofen) at E9.5 served as 
control.  
In vitro – 1) For primary epithelial cell experiments in rats, a single cell suspension was obtained 
at E14.5 from pooled lungs of control or nitrofen-injured rat fetuses by trypsinization. Cells were 
subjected to serial fibroblast depletions as described (40, 62). 2) For organoid studies, cells were 
seeded in a ratio of 60:40 semi-solid Matrigel to medium, as described (63). Cells from nitrofen-




rAFSC-EVs or rMSC-EVs (1.2% v/v).  Lung organoids from fetuses whose mothers had not 
received nitrofen served as control. 3) A549 cells were treated for 24 h with nitrofen (40 µM), 
and treated with medium alone, or medium supplemented with hAFSC-EVs or hMSC-EVs 
(0.5% v/v). Uninjured and untreated A549 cells served as control. 4) HPAEpiCs were obtained 
from the lung of a 21-week-gestation fetus and used at first passage. Cells were injured with 400 
µM nitrofen for 24 hours, and treated with medium alone, or medium supplemented with 
hAFSC-EVs or hMSC-EVs (0.5% v/v).  
In vivo - Pulmonary hypoplasia was induced by surgical creation of CDH at E25 in New Zealand 
rabbits (41). At E27, tracheal ligation was performed alone or after intra-tracheal administration 
of a 50 µL bolus containing rAFSC-EVs, rMSC-EVs, or hAFSC-EVs (Movie S4). Lungs were 
harvested at E31 and frozen for RNA extraction or fixed in 4% paraformaldehyde and embedded 
in paraffin. 
Outcome measures 
For lung morphometry, rat fetal lung explants were imaged by differential interference contrast 
microscopy and independently assessed by two blinded researchers for terminal bud density and 
surface area using ImageJ, as described (27). Rabbit fetal lungs were blindly evaluated with 
histology (hematoxylin/eosin) to assess alveolar density and wall thickness, as described (64, 
65). For RNA expression, factors involved in rat or rabbit lung branching morphogenesis were 
assessed with quantitative polymerase chain reaction (qPCR). To investigate cellular 
homeostasis on lung explants and organoids, we used 5-ethynyl-2'-deoxyuridine (EdU) 
incorporation, viability/cytotoxicity staining, terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL assay), or Ki67+ immunostaining. To assess epithelial differentiation, lung 




immunostained for SPC and CC10. To study rat EV protein cargo, we used nanoscale liquid 
chromatography coupled to tandem mass spectrometry and performed differential expression 
analysis (1% protein and peptide false discovery rate, FDR). For rat EV RNA cargo, we 
conducted small RNA-sequencing and compared RNA content using Bioconductor DESeq. To 
study rAFSC-EV RNA effects on target cells, total RNA was isolated from primary lung 
epithelial cells from each condition and used edgeR for comparative analyses. To study changes 
in miRNA expression patterns in the same target cells, we further analyzed the Nitrofen and 
Nitrofen+rAFSC-EVs treated cells using small RNA-sequencing. edgeR was used to determine 
miRNA expression changes (FDR < 0.1), and Spearman’s correlation was used to assess 
potential gene targets of detected miRNAs in cells. Pathway enrichment analysis was conducted 
with g:profiler and miRNA-mRNA network analysis was performed with TargetScan, 
miRTarBase, and Cytoscape. 
Statistical Analysis 
Groups were compared using two-tailed Student t-test, Mann-Whitney test, one-way ANOVA 
(Tukey post-test), or Kruskal-Wallis (post-hoc Dunn’s nonparametric comparison) test according 
to Gaussian distribution assessed by D’Agostino-Pearson omnibus normality test. For correlation 
studies, a Pearson coefficient was reported as r (confidence interval). P value was considered 
significant when p<0.05. All statistical analyses were produced using GraphPad Prism® software 
version 6.0. mRNA and miRNA sequencing analyses in lung epithelial cells were performed in R 
(version 3.6.0). Package “edgeR” (version 3.26.5) was used for differential analyses between two 





Fig. S1. Characterization of rAFSC-EVs and rMSC-EVs and effects on lung explants based on 
size and concentration. 
Fig. S2. Effects of rAFSC-EVs on control lung explants and primary lung epithelial cells. 
Fig. S3. Effects of rMSC-EV administration on in vitro and ex vivo models of pulmonary 
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Fig. S4. Analysis of protein and RNA cargo of rAFSC-EV and rMSC-EV. 
Fig. S5. Enrichment plots for RNA-seq analysis of rMSC-EV treated primary lung epithelial 
cells and effects on in vivo model of pulmonary hypoplasia. 
Fig. S6. Correlation analysis of miRNA-mRNA sequencing in primary lung epithelial cells. 
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Fig. 1. Administration of rAFSC-EVs promotes growth, branching morphogenesis, and 
maturation in fetal hypoplastic lungs. (A) Representative light microscopy photos of lung 
explants harvested at E14.5 (0 h) and grown for 72 h in conditions indicated in columns. Scale 
bar = 750 µm. (B and C) quantification of total terminal bud count and total lung surface area 
measured at 72 h. ****P<0.0001, **P<0.01, ns= P>0.05. Data are quantified blindly by two 
investigators for the following number of biological replicates: Control (n=16), Nitrofen (n=17), 
Nitrofen+rAFSC-CM (n=12), Nitrofen+rAFSC-EVs (n=12), Nitrofen+EV-depleted rAFSC-CM 
(n=5), Nitrofen+rMSC-EVs (n=8). (D) Gene expression changes in lung maturation markers 
fibroblast growth factor 10 (Fgf10) and vascular endothelial growth factor (Vegfa), and its 
receptors (Flt1 and Kdr) in lung explants measured at 72 h. *P<0.05, ***P<0.001. Expression 
values of at least n=9 technical replicates are shown (E to G) Immunofluorescence co-stain 
experiment of proliferating cells and distal lung epithelium progenitor cells of lung explants 
(SOX9, green; EdU, pink, DAPI nuclear stain, blue; scale bar = 100 µm), quantified through 
number of EdU+ cell per DAPI and SOX9 fluorescence intensity (AU = arbitrary units). N=4 
biological replicates were used with a total of 50x50 µm fields covering entire lung sections as 
indicated: Control (n=157), Nitrofen (n=222), Nitrofen+rAFSC-EVs (n=128). (H and I) Western 
blot analysis of SOX9 and SPC expression in lung explants grown for 72 h, quantified by signal 
intensity normalized to GAPDH in at least n=3 biological replicates from each condition. (J and 
K) Immunofluorescence experiment of surfactant protein C (SPC) expressing cells in lung 
explants (SPC, green; DAPI nuclear stain, blue; scale bar =100 µm), quantified by fluorescence 
intensity: Control (n=6), Nitrofen (n=4), Nitrofen+rAFSC-EVs (n=4). (L) Quantification of SPC 




each condition. (M and N) TUNEL immunofluorescence experiments on lung explants grown 
for 72 h, quantified by TUNEL+ cells per DAPI in n=4 biological replicates with a total of 50x50 
µm fields covering entire lung sections as indicated: Control (n=311), Nitrofen (n=240), 
Nitrofen+rAFSC-EVs (n=107). Groups were compared using Kruskal-Wallis (post-hoc Dunn’s 
nonparametric comparison) test for Fig. 1 B, C, F, G, I, K, L, N, and with one-way ANOVA 
(Tukey post-test) for Fig. 1 D, according to Gaussian distribution assessed by D’Agostino 






Fig. 2. rAFSC-EVs maintain homeostasis and stimulate differentiation of the epithelium 
from hypoplastic fetal lungs. (A) Proliferation rate of primary lung epithelial cells from control 
and nitrofen-injured hypoplastic lungs treated with rAFSC-CM, rAFSC-EVs, EV-depleted 
rAFSC-CM [5’EdU labeling, Control (n=7), Nitrofen (n=5), Nitrofen+rAFSC-CM (n=3), 
Nitrofen+rAFSC-EVs (n=5), Nitrofen+EV-depleted rAFSC-CM (n=3)]. ****P<0.0001, ns= 
P>0.05. (B) Cell death rate of primary lung epithelial cells from control and nitrofen-injured 
hypoplastic lungs treated as in (A) [live/dead cytotoxicity assay, Control n=5, Nitrofen (n=5), 
Nitrofen+rAFSC-CM (n=6), Nitrofen+rAFSC-EVs (n=5), Nitrofen+EV-depleted rAFSC-CM 
(n=4)]. *P<0.05, ***P<0.001. (C) Light microscopy photos of fetal rat lung organoids derived 
from control lungs and nitrofen-injured hypoplastic lungs either treated with medium alone 
(Nitrofen) or medium supplemented with rAFSC-EVs (Nitrofen+rAFSC-EVs). Scale bar = 100 
µm. Representative photo of Control (n=108), Nitrofen (n=63), Nitrofen+rAFSC-EVs (n=94). 
(D) Proliferation of cells in organoids evaluated with immunofluorescence (Ki67 staining, green; 
scale bar= 50 µm) and quantified as percentage of Ki67+ cells per total number of DAPI (blue) 
stained nuclei in Control (n=8), Nitrofen (n=7), Nitrofen+rAFSC-EVs (n=9). (E) SPC staining in 
organoids (green; DAPI nuclear stain, blue; scale bar = 50 µm) quantified with fluorescence 
intensity calculated from total corrected cellular fluorescence from Control (n=30), Nitrofen 
(n=31), Nitrofen+rAFSC-EVs (n=25) (AU= arbitrary units). (F) CC10+ cells in organoids (green; 
DAPI nuclear stain, blue; scale bar = 50 µm) quantified with fluorescence intensity calculated 
from total corrected cellular fluorescence Control (n=30), Nitrofen (n=30), Nitrofen+rAFSC-EVs 
(n=30). Groups were compared using Kruskal-Wallis (post-hoc Dunn’s nonparametric 
comparison) test for Fig. 2 A, B, D, E, F according to Gaussian distribution assessed by 




Fig. 3. The role of RNA cargo released by rAFSC-EVs. (A and B) Fluorescently labeled 
rAFSC-EV protein (green) and RNA (red) cargo entered primary lung epithelial cells (DAPI 
nuclear stain, blue; scale bar = 100 µm). Cells were outlined based on light microscopy images 
to highlight the border. To confirm this, cells were washed twice with PBS and fixed in 4% PFA 
and re-imaged after live cell imaging (shown in Movie S2 and Movie S3). (C) Bioanalyzer 
traces of RNase pre-treated rAFSC-EVs. (D to I) Representative photos of gold immunolabeling 
experiments of RNase-treated rAFSC-EVs in far field (D) and near field (E to H) or rAFSC-EVs 
in near field (I), using transmission electron microscopy, with TSG101 (10 nm), and RNase (25 
nm), scale bar = 100 nm. Controls include single stains (F and G), secondary only antibodies 
(H), and co-stains in untreated rAFSC-EVs (I). Photos are representative of four biological 
replicates of rAFSC-EV-RNase and rAFSC-EVs (J to M) Effects of RNase pre-treated rAFSC-
EVs on lung growth parameters (bud count, (J); and surface area, (K), from Control (n=16), 
Nitrofen (n=17), Nitrofen+rAFSC-EVs (n=12), and Nitrofen+rAFSC-EV-RNase (n=4), and on 
pulmonary epithelial cells (proliferation, (L); and cell death rate (M) from Control (n=7), 
Nitrofen (n=5), Nitrofen+rAFSC-EVs (n=5), and Nitrofen+rAFSC-EV-RNase (n=4), 
****P<0.0001, ***P<0.001, **P<0.01, ns= P>0.05. (N) Small RNA-sequencing analysis of 
rAFSC-EVs and rMSC-EVs separated by type of RNA species. Solid bar represents proportion 
of significantly different species per type of RNA. (O) Heat map of miRNAs detected in rAFSC-
EVs (n=3) and rMSC-EVs (n=2), ranked based on fold change and significant difference 
between the two populations. The two inlets report the miRNAs involved in lung development 
(see table S2). Right inlet: miRNAs significantly enriched in rAFSC-EVs detected within the top 
50 miRNAs. Left inlet: miRNAs equally abundant in rAFSC-EVs and rMSC-EVs detected 




nonparametric comparison) test for Fig. 3 J, K, L, M according to Gaussian distribution assessed 





Fig. 4. Effects of rAFSC-EVs exerted on primary lung epithelial cells. (A) Heat map of 
mRNA expression of genes from lung epithelial cells of nitrofen-injured lungs treated with 
rAFSC-EVs from n=6 biological replicates each, FDR < 0.1. Color represents row-scaled, 
normalized read counts (RPKM). (B) GSEA enrichment plot of epithelial cell differentiation 
generated with genes ranked by fold change between NA vs. N. “Leading edge” genes are shown 
on the side. (C) Interaction network of rAFSC-EV miRNAs and down regulated genes in 
nitrofen-injured lung epithelial cells treated with rAFSC-EVs. Size of node represents number of 
connections. Blue nodes represent genes down-regulated (FDR < 0.1) in nitrofen-injured lung 
epithelial cells treated with rAFSC-EVs compared to nitrofen-injured lung epithelial cells. White 
nodes represent miRNAs that were detected in the rAFSC-EV cargo. Green nodes represent 
miRNAs that were detected in rAFSC-EV cargo that had higher expression in rAFSC-EV-treated 
nitrofen-injured lung epithelial cells compared to untreated nitrofen-injured epithelial cells. 
Triangles represent miRNAs from the miR17~92 family and paralogues. Each miRNA-gene 
target pair is connected by a gray edge and pairs containing a miRNA from miR17~92 family or 





Fig. 5. Towards the clinical translation of AFSC-EVs as treatment for fetal lung 
regeneration. (A) Schematic of experimental groups from the rabbit model of CDH. (B) 
Representative histology images (hematoxylin/eosin) of fetal lungs from control rabbits and from 
rabbits that underwent surgical CDH creation and were either untreated (CDH), or subjected to 
tracheal occlusion (CDH+TO), or were administered rAFSC-EVs prior to tracheal occlusion 
(CDH+TO+rAFSC-EVs). Each condition included fetal lungs from n=9 experiments. Scale bar = 
500 µm. (C and D) Differences in number of alveoli (radial alveolar count) were quantified in at 
least 12 counts per fetal lung in 2 different sections of the lung, and thickness of the alveolar wall 
(mean wall transection length) was measured in 10 different areas of each lung. **P<0.01, 
*P<0.05. (E and F) Gene expression changes in alveolar lipofibroblasts (PLIN2), BMP (bone 
morphogenetic protein) signaling (BMP2, BMP4, Id1) in n=9 biological replicates of each 
condition. ***P<0.001 (G and J) Effects of good manufacturing practice-grade hAFSC-EVs on 
proliferation rate and viability rate on nitrofen-injured human A549 cells (G and H), and human 
pulmonary alveolar epithelial cells (I and J) (n>30 technical replicates). (K and L) Uptake of 
hAFSC-EVs fluorescently labeled with PKH26 by A549 cells or human pulmonary alveolar 
epithelial cells. Scale bar = 25 µm. Groups were compared using Kruskal-Wallis (post-hoc 
Dunn’s nonparametric comparison) test for Fig. 5 C, D, E, F, H, I, and J, and with one-way 
ANOVA (Tukey post-test) for Fig. 5 G according to Gaussian distribution assessed by 





Fig. 6. Schematic of changes that occur with AFSC-EV administration to hypoplastic fetal 
lungs. (A) Untreated hypoplastic lungs with few lung buds, small total surface area, and 
dysregulated homeostasis (low cell proliferation, high cell death, undifferentiated epithelial and 
fibroblast cells). (B) Administration of AFSC-EVs to hypoplastic lungs improves terminal 
branching and results in increased number of lung buds, higher surface area, and restored cellular 
homeostasis (improved cell proliferation, reduced cell death, more differentiated epithelial and 
fibroblast cells). 
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Extended Materials and Methods 
Cells  
Rat amniotic fluid stem cells (rAFSCs) were isolated from amniotic fluid of E12 Sprague-
Dawley rat fetuses as described (66), and grown in alpha-Minimal Essential Media (αMEM, 
Gibco, ThermoFisher, Waltham, MA) supplemented with 20% Chang supplements (Irvine 
Scientific, Santa Ana, CA), 15% fetal bovine serum (FBS, ThermoFisher Scientific, Waltham, 
MA), and 0.5% Penicillin/Streptomycin (ThermoFisher Scientific, Waltham, MA). Human 
AFSCs (hAFSCs) were obtained under good manufacturing practice guidelines as described 
(UCL/UCLH REC Reference: 08/0304) (22). Sprague-Dawley rat bone-marrow derived 
mesenchymal stem cells (MSCs) were purchased (CellBiologics, Chicago, IL) and grown in 
supplier recommended medium until 90% confluence. Human adenocarcinomic alveolar basal 
epithelial cells (A549) were purchased (Sigma Aldrich, Missouri, MO) and grown in Dulbecco's 
Modified Eagle Medium, (DMEM) with Nutrient Mixture F-12 media (Gibco, ThermoFisher, 
Waltham, MA) supplemented with 10% FBS and 0.5% Penicillin/Streptomycin. All cells were 
used within 6 passages. Human pulmonary alveolar epithelial cells (HPAEpiC) were obtained 
from the lungs of a healthy fetus at 21 weeks of gestation (ScienCell, Carlsbad, CA), grown in 
supplier recommended medium, and used immediately for proliferation and viability assays. 
Human bone marrow-derived MSCs were obtained from a healthy donor (ATCC, Manassas, 
Virginia) and grown in supplier recommended medium. Human MSCs were used within three 
passages. 
Extracellular vesicles (EVs) 
EVs from rat and human AFSCs and from MSCs were isolated by ultracentrifugation from cells 




described (29). Based on previous studies and confirmed in this study, we established that 4x106 
AFSCs cultured under these conditions secrete approximately 3x109 ± 1x107 EVs, as quantified 
by nanoparticle tracking analysis (29). For all in vitro, ex vivo, and in vivo experiments herein 
described, we administered 50 µL of the EV preparation that corresponds to 0.5% of the 
conditioned medium (50 µL EV volume of 10 mL CM volume, v/v) and 1.5x108 ± 5x105 EVs. 
For in vitro organoid experiments, the dose was 3.6x108 ± 1.2x106 EVs.  
EVs used in this study were characterized for size by nanoparticle tracking analysis, morphology 
by transmission electron microscopy, and expression of canonical EV-related markers by 
Western blot (fig. S1), as described (29) and recommended by the International Society for 
Extracellular Vesicles. Small EVs had a mean size of 140 ± 5 nm and mode size 104 ± 11 nm. 
To isolate medium/large EVs (m/lEVs, >200 nm), sucrose gradient ultracentrifugation was used 
with six layers ranging from 10% to 90% sucrose in phosphate-buffered saline (PBS). rAFSC-
CM was spun through this gradient at 100,000 g for 14 h. Fractionated layers were isolated and 
nanoparticle tracking analysis was used to confirm the presence of large vesicles (m/lEVs mean 
size of 363 ± 17 nm, mode size 217 ± 32 nm). 
Ex vivo model of pulmonary hypoplasia 
In fetal rats, pulmonary hypoplasia was induced as described (30, 40) with the administration of 
nitrofen (Sigma Aldrich, Missouri, MO) to pregnant Sprague-Dawley rats (100 mg in 1 mL olive 
oil; protocol #39168, #49892). At E14.5, the dam was euthanized, and fetal lungs were 
harvested. Lungs were washed in PBS, grown on 0.8 µm nanofilter membranes, and incubated 
for 72 h in culture medium alone (DMEM), rAFSC-CM, or medium supplemented with rAFSC-
EVs or rMSC-EVs (0.5% v/v). For AFSC co-culture experiments, five thousand rAFSCs were 




top of the cells and allowed to float for 72 h. Fetal lungs from dams that received olive oil (no 
nitrofen) at E9.5 served as control.  
In vitro model of pulmonary hypoplasia 
At E14.5, a single cell suspension was obtained from pooled lungs of control or nitrofen-injured 
rat fetuses by trypsinization (0.25% Trypsin-EDTA, ThermoFisher, Waltham, MA) for 20 
minutes. Cells were spun down by centrifugation (5 minutes, 800 g) and the pellet was 
resuspended in DMEM supplemented with 10% FBS and subjected to three serial depletions of 
fibroblasts by incubation for 1 h each following an established protocol (40, 62). Cells were used 
to test epithelial homeostasis and to generate fetal lung organoids for assessment of epithelial cell 
differentiation. For epithelial homeostasis experiments, cells were grown for 5 days in Bronchial 
Epithelial Cell Growth Medium (BEGM; Lonza, Basel Switzerland). Cells were checked daily 
for proper epithelial morphology using a light microscope. On the fifth day, cells were confirmed 
to be positive for SPC and negative for vimentin via immunofluorescence staining assays. 
Epithelial homeostasis was investigated by assessing cell proliferation and cell death as 
described (40) on cells from nitrofen-injured lungs that either had their medium replaced with 
BEGM, or BEGM supplemented with 500 µL of rAFSC-CM, 500 µL of EV-depleted rAFSC-
CM, rAFSC-EVs, or rMSC-EVs (0.5% v/v). For AFSC co-culture experiments, rAFSCs were 
seeded in the top compartment of a transwell (0.4 µm) and primary lung epithelial cells were 
seeded in the bottom compartment (in a ratio of 1:10, rAFSC to primary lung epithelial cells), as 
described (40). 
For epithelial differentiation experiments, cells were seeded in a ratio of 60:40 semi-solid 
Matrigel (Corning, Corning, NY) to medium ratio, to generate organoids as described (63). Cells 




supplemented with 1.2% v/v rAFSC-EVs or rMSC-EVs. Lung organoids from untreated fetuses 
served as control. Medium was replaced every other day.  
Human A549 cells were injured for 24 h with nitrofen (40 µM), and subsequently administered 
medium alone, hAFSC-EVs or hMSC-EVs (0.5% v/v). Untreated and uninjured A549 cells 
served as control. Following 24 h incubation, proliferation and cell death rates were determined 
by EdU incorporation kit (Click-IT®, ThermoFisher Scientific, Waltham, MA), and Live/Dead 
cell viability assay (ThermoFisher Scientific, Waltham, MA), as described (40). Experiments 
were repeated for control (n=4), medium only (n=4), hAFSC-EVs (n=4), hMSC-EVs (n=4), and 
included >30 technical replicates.   
HPAEpiC from a fetus at 21 weeks of gestation contained both alveolar type I and type II cells, 
which were selected with cytokeratin-18 and cytokeratin-19 by the supplier. Cells were grown in 
supplier recommended medium and used in the first passage after reaching ~70% confluence. 
HPAEpiC were stressed with nitrofen exposure at 400 µm (dosage at 40 µm was not optimal in 
inducing impairment in cell proliferation or viability). Experiments were repeated for control 
(n=6), medium only (n=6), hAFSC-EVs (n=4), hMSC-EVs (n=4), and included >100 technical 
replicates.   
In vivo model of pulmonary hypoplasia 
In fetal rabbits, pulmonary hypoplasia was induced secondary to surgical creation of a 
diaphragmatic hernia at embryonic day E25 in New Zealand rabbits, following ethical approval 
(protocol #191/2018, #40/2020), as described (41). Two days later at E27, tracheal ligation was 
performed either alone or in conjunction with EV administration [rAFSC-EVs (n=9), rMSC-EVs 
(n=8), or hAFSC-EVs (n=5)]. EVs (50 µL) were injected intra-tracheally prior to ligation of the 




extractions or were fixed in 4% paraformaldehyde and embedded in paraffin. Fetal rabbits with 
intact diaphragms and that did not receive tracheal occlusion served as control. 
Lung morphometry 
In fetal rats, lung explants from different conditions were compared for terminal bud density and 
surface area using ImageJ independently by two blinded researchers, as described (27). Terminal 
branching was measured by counting the number of terminal buds defined as the number of 
single acini separated by distinct septae at the periphery of the explant (27). Differential 
interference contrast photos were taken on a light microscope (Leica DMI6000B, Wetzlar, 
Germany) at 2.5X magnification. Experiments were repeated as many times as indicated: control 
(n=16), medium only (n=17), rAFSC-CM (n=12), medium supplemented with 0.5% v/v rAFSC-
EVs (n=12), EV-depleted rAFSC-CM (n=5), RNase-treated rAFSC-EVs (n=4), rMSC-EVs 
(n=8), medium supplemented with 0.25% v/v rAFSC-EVs AFSC-EVs (n=5), medium 
supplemented with 0.05% v/v rAFSC-EVs (n=5), rAFSC-m/lEVs (n=4), and co-cultured rAFSCs 
(n=7). 
Rabbit fetal lungs were blindly evaluated with histology (hematoxylin and eosin stain staining) 
to assess the number of alveoli and the thickness of the alveolar wall, as measures of the degree 
of lung alveolarization. For the number of alveoli, the radial alveolar count (RAC), a well-
established index of alveolar number within the acinus (64), was determined in at least 12 counts 
per fetal lung in 2 different sections of the lung. For the thickness of the alveolar wall, the mean 





Lung explants from fetal rats and freshly harvested lungs of fetal rabbits were frozen at -20 °C. 
Total RNA was isolated using Trizol reagent (ThermoFisher Scientific, Waltham, MA), 
following supplier recommended protocols. Purified RNA was quantified using a NanoDrop™ 
spectrophotometer (ThermoFisher Scientific, Waltham, MA) and cDNA synthesis was 
performed with 200 ng for rat and 1 µg for rabbit quantified RNA (superscript VILO cDNA 
synthesis kit, ThermoFisher Scientific, Waltham, MA). qPCR experiments were conducted with 
SYBR™ Green Master Mix (Wisent, Saint-Jean-Baptiste, QC) for 40 cycles (denaturation: 95 
°C, annealing: 58 °C, extension: 72 °C) using the primer sequences reported in table S6. Melt 
curve plots were used to determine target specificity of the primers. ΔΔCT method was used to 
determine normalized relative gene expression.  
To determine the expression of specific miRNAs in EVs and parent cells, RNA was extracted 
from approximately 4 million cells of rAFSCs and rMSCs (n=3 replicates each) using the 
Nucleospin miRNA kit (Macherey-Nagel, Düren, Germany), following supplier recommended 
protocols. EV RNA was isolated using the same procedure, from CM of the corresponding 
parent cells (n=3 replicates each). cDNA was synthesized using miRCURY LNA RT kit 
(Qiagen, Hilden, Germany) and UniSp6 RNA Spike-in controls were used. Expression of miR-
17-5p (YP02119304), miR-18a-5p (YP00204207), miR-19b-3p (YP00204450), miR-20a-5p 
(YP00204292), and controls Rnu5g (YP00203908) was assessed with miRCURY LNA SYBR® 
Green PCR Kit (Qiagen, Hilden, Germany), following supplier recommended protocols. 40-
cycle qPCR was conducted as described above, and ΔΔCT method was used to determine 





Rat lung explants were fixed using 4% paraformaldehyde for 18 h, washed in PBS, and 
incubated in 30% sucrose for at least 18 h. Optimal cutting temperature compound (Electron 
Microscopy Sciences, Hatfield, PA) embedded lungs were cryosectioned in coronal orientation 
and stained with primary antibodies reported in table S7. Fetal lung organoids were fixed in 4% 
paraformaldehyde for 30 minutes, permeabilized in 0.5% triton X (Sigma Aldrich, Missouri, 
MO) and 0.05% Tween-20 (Sigma Aldrich, Missouri, MO) in PBS, pre-blocked in 1% bovine 
serum albumin (BSA; Sigma Aldrich, Missouri, MO) with 0.2% triton-X and 0.05% Tween-20 
in PBS. Organoids were stained with primary antibodies reported in table S7. A Leica SP8 
lightning confocal microscope (Wetzlar, Germany) was used to image samples using the same 
laser power and exposure across conditions. Wherever possible, z-stacks were taken to increase 
coverage of tissues. Total corrected cellular fluorescence was calculated to compare the 
fluorescence intensities between conditions, as described (67) using ImageJ 1.51.  
Proliferation and apoptosis experiments on lung explants 
Proliferation experiments in explants were conducted with the addition of EdU (10 µM final 
concentration in medium) to lung explants cultures 3 h prior to the 72 h endpoint of experiments. 
Explants were then fixed and processed for immunofluorescence assays as stated above. The 
Click-iT™ protocol was used to label EdU+ cells (2.4:1000, Alexa Fluor™ 647) in co-staining 
experiments with SOX9 (1:1000, Alexa Fluor™ 488), as recommended by the supplier. Lung 
explants from n=4 biological replicates were used in at least triplicate technical replicates for 
analysis. Quantification of EdU signal was conducted with HistoQuant in QuantCenter Imaging 
Software (3D Histech, Budapest, Hungary) and covered >100 50x50 µm fields.  
Cell apoptosis experiments on lung explants were conducted with the Click-iT™ TUNEL assay 




explants from n=4 biological replicates were used in at least triplicate technical replicates for 
analysis. Alexa Fluor™ 647 was used in co-staining experiments. Quantification of TUNEL 
signal was conducted with HistoQuant in QuantCenter Imaging Software (3D Histech, Budapest, 
Hungary) and covered >100 50x50 µm fields.  
Protein expression 
Protein from lung explants was isolated by re-suspending explants in cell extraction buffer 
(ThermoFisher Scientific, Waltham, MA) supplemented with protease inhibitors (Sigma Aldrich, 
Missouri, MO), and sonicating for 3 cycles of 10 seconds each. Protein was quantified using the 
Pierce Bradford Assay (ThermoFisher Scientific, Waltham, MA), and 20 µg of protein from each 
sample was processed as described (29) and probed for SPC and SOX9 (table S7; Data file S5). 
Expression of canonical EV markers CD63, Hsp70, Flo-1, and TSG101 in rAFSC-EVs and 
rMSC-EVs, and the nuclear marker H3K27me3 that indicates cellular debris, were analyzed as 
described (29). EV preparations did not have expression of H3K27me3, demonstrating that the 
preparations are free of cell debris. All details for the antibodies are available in table S7. 
EV characterization and staining 
To track EV migration into primary lung epithelial cells and lung explants, EV cargoes were 
fluorescently labelled for RNA and protein using Exo-Glow™ (System Biosciences, Palo Alto, 
CA) and for lipid membrane using PKH26 red fluorescent cell linker (Sigma Aldrich, Missouri, 
MO) following supplier recommended protocols. For PKH26 staining, EVs isolated using 
ultracentrifugation were re-suspended in Diluent C, stained with PKH26 for five minutes with 
periodic mixing, then the reaction was stopped with 1% BSA in water. Starting samples 
containing water only were used as negative controls for staining procedures. For live cell 




Fitchburg, WI). DAPI was added in culture medium for 10 minutes (2% in medium), and then 2 
µg of EVs stained with ExoGlow RNA or ExoGlow Protein were added and imaged once every 
two seconds for 10 minutes using a Leica SP8 lightning confocal microscope. After live cell 
imaging was performed, cells were washed twice with PBS and fixed in 4% PFA, and re-imaged 
to visualize the internalization of the stained EVs. 
Role of rAFSC-EV RNA Cargo 
To determine the role of RNA in rescuing pulmonary hypoplasia, rAFSC-EVs were treated with 
RNase-A (ThermoFisher, Waltham, MA) at 2 µg/µL for 90 minutes, then with RNase inhibitor 
(ThermoFisher, Waltham, MA) as described (68). Data shown in viability and proliferation 
assays are representative of n=3 technical replicates, with at least 5 fields per experiment. 
Bioanalyzer analysis (Agilent Technologies, Santa Clara, CA) was used to test effectiveness of 
RNA degradation, after total RNA isolation using miRvana miRNA isolation kit as described 
above. Untreated EVs that were exposed to all temperature changes without the addition of 
RNase-A were used as control.  
To confirm the entry of RNase into rAFSC-EVs, TSG101 and RNase were probed by immuno-
EM labelling. Samples were prepared for TEM following established protocols (29). Briefly, 
fixed EV preparations (rAFSC-EVs or RNase-treated rAFSC-EVs) were allowed to absorb onto 
charged EM grids for 1 h. All reagents were pre-filtered using 0.22 µm syringe filters. Samples 
were washed in PBS, permeabilized in 0.05% triton-X in PBS for 30 minutes, washed five times 
in PBS, and then incubated for 2 h in primary antibody (1:100 in 10% BSA-c; Aurion, 
Wageningen, Netherlands) with TSG101, RNase, or both (table S7). Following five washes in 
PBS, samples were incubated for 1 h with the corresponding secondary antibodies (1:25 in 10% 




10 minutes. Following ten washes in distilled water, grids were contrasted and embedded in 
uranyl oxalate for 10 minutes, methyl cellulose-uranyl acetate for 10 minutes, and then prepared 
for EM imaging on a Tecnai 20 (FEI, Hillsboro, OR) from 25 kx to 100 kx magnification. Four 
biological replicates of rAFSC-EV-RNase and rAFSC-EVs, which included four technical 
replicates each, were included in these experiments. Experimental groups included single stains, 
and only secondary antibody stains (incubation with serum alone). Experiments were optimized 
for incubation time and antibody concentrations. Gold tags were identified and measured 
manually using the Tecnai 20 Software.  
To determine if there was a carry-over effect of the RNase-A treatment on rAFSC-EVs, we 
performed an additional step and separated the enzymatically treated rAFSC-EVs from the 
supernatant, which presumably contained the inactivated RNase-A. This supernatant was then 
administered to the control primary lung epithelial cells, and proliferation rate was determined as 
described above. 
Profiling of rAFSC-EVs and rMSC-EVs 
10 mL of rAFSC-CM or rMSC-CM was centrifuged at 1500 g for 5 min to remove residual cells 
and debris. The supernatant was transferred to a new 50 mL conical tube for EV isolation. 
Isolations were conducted in triplicate. ExoQuick-TC (System Biosciences, Palo Alto, CA) was 
added to the supernatant at 1:5 ratio (ExoQuick:Supernatant), mixed gently, and allowed to 
incubate for 18 h at 4 °C. After 24 h, the admixture was centrifuged at 1500 g for 30 min to 
separate EVs. 




EVs were quantified for protein concentration using Qubit fluorometry (Invitrogen, Carlsbad, 
CA). 10 µg of EV protein was processed by SDS-PAGE using 10% Bis Tris NuPage mini-gel 
(Invitrogen, Carlsbad, CA) in the MES buffer system. The migration window (2 cm lane) was 
excised and in-gel digestion was performed using a ProGest robot (DigiLab, Hopkinton, MA) 
with the following protocol: 1) Washed with 25 mM ammonium bicarbonate followed by 
acetonitrile. 2) Reduced with 10 mM dithiothreitol at 60 °C followed by alkylation with 50 mM 
iodoacetamide at room temperature. 3) Digested with trypsin (Promega, Madison, WI) at 37 °C 
for 4 h. 4) Quenched with formic acid and the supernatant was analyzed directly without further 
processing. 
The digested protein samples were analyzed by nanoscale liquid chromatography coupled to 
tandem mass spectrometry (MS) with a Waters NanoAcquity High Performance Liquid 
Chromatography system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a 
trapping column and eluted over a 75 µm analytical column at 350 nL/min using a 2 h reverse 
phase gradient; both columns were packed with Luna C18 resin (Phenomenex, Torrance, CA). 
The mass spectrometer was operated in data-dependent mode, with the Orbitrap operating at 
60,000 and 17,500 full width at half maximum for MS and MS/MS respectively. The fifteen 
most abundant ions were selected for MS/MS. Data were searched using Mascot, and parsed into 
Scaffold (Proteome Software) for validation, filtering and to create a non-redundant list per 
sample. Data was filtered using 1% protein and peptide false discovery rate (FDR) and required 
at least two unique peptides per protein. A minimum of three spectral count values greater than 0 
in at least one of the groups was considered significantly different, and a t-test was performed on 
these values. For protein pathway enrichment analysis, 222 proteins that were differentially 




plot the top significantly enriched pathways for Biological Processes, Cellular Component, and 
Molecular Functions.  
RNA-sequencing of EV cargo 
Total RNA was isolated using the SeraMir Exosome RNA Purification Column kit (System 
Biosciences, Palo Alto, CA) according to the manufacturer’s instructions. For each sample, 1 µL 
of the final RNA eluate was used for measurement of small RNA concentration by Agilent 
Bioanalyzer Small RNA Assay using Bioanalyzer 2100 Expert instrument (Agilent 
Technologies, Santa Clara, CA). 
Small RNA libraries were constructed with the CleanTag Small RNA Library Preparation Kit 
(TriLink, San Diego, CA) according to the manufacturer's protocol. The final purified library 
was quantified with High Sensitivity DNA Reagents (Agilent Technologies, Santa Clara, CA) 
and High Sensitivity DNA Chips (Agilent Technologies, Santa Clara, CA). The libraries were 
pooled, and the 140 base pair to 300 base pair region was size selected on an 8% TBE gel 
(Invitrogen, Carlsbad, CA). The size selected library is quantified with High Sensitivity DNA 
1000 Screen Tape (Agilent Technologies, Carlsbad, CA), High Sensitivity D1000 reagents 
(Agilent Technologies, Carlsbad, CA), and the TailorMix HT1 qPCR assay (SeqMatic, Fremont, 
CA), followed by a NextSeq High Output single-end sequencing run at SR75 using NextSeq 
500/550 High Output v2 kit (Illumina, San Diego, CA) according to the manufacturer's 
instructions.  
Following an initial quality assessment with bioinformatics tool FastQC, n=3 biological 
replicates of rAFSC-EVs and n=2 biological replicates of rMSC-EVs were included in the final 
analysis. Bowtie2 was used to map the spike-in DNA, and the reads were trimmed and filtered to 




PRINSEQ). After trimming, reads were mapped using open-source software 
(Bedtools/SAMtools). DESeq was used for differential expression analysis with default settings.  
Primary Lung Epithelial Cell RNA-sequencing Experiments 
Primary lung epithelial cells from nitrofen-injured lungs and normal control lungs were isolated 
as described above, grown in PneumaCult™ Ex Plus Medium, and treated with medium 
supplemented with rAFSC-EVs or rMSC-EVs (0.5% v/v). Total RNA extraction was conducted 
on n=6 biological replicates of each condition. RNA was extracted using Nucleospin miRNA kit 
(Macherey-Nagel, Düren, Germany) following supplier recommended protocols. Purified RNA 
was quantified using NanoDrop, and Bioanalyzer was used to assess the quality of RNA. 
Samples with RNA integrity number of > 9 were used to construct libraries. For library 
construction, we used an automated NEBNext Ultra II Directional with polyA isolation (New 
England BioLabs) using the Agilent NGS Workstation (Agilent Technologies) as per 
manufacturer's protocol. Briefly, 250 ng of total RNA spiked-in with SIRVs (Spike-in RNA 
Variant Control Mixes, Set3, Lexogen) as per manufacturer’s protocol was used to generate 
complementary DNA (cDNA). cDNA was amplified with 12 PCR cycles. The resulting libraries 
were quantified with Qubit DNA HS (ThermoFisher). Fragment sizes were analyzed on the 
Agilent Bioanalyzer using the High Sensitivity DNA assay prior to sequencing. Paired-end 
sequencing was performed by The Centre for Applied Genomics, The Hospital for Sick 
Children, Toronto, Canada on a NovaSeq 6000 S2 flowcell (Illumina) with a read length of 100 
base pairs. 25-35 million paired end reads were obtained for each library. Sequencing quality 
was examined using FastQC and qualimap (see data file S2 for detailed QC metrics on 
sequencing libraries). Reads were aligned to the rat genome (rnor6, obtained from UCSC 




settings. Reads were assigned to genes using featureCounts (version 1.5.3) with parameters “-p –
B –s 2 –Q 255”. Gene models were obtained from Ensembl (Rnor_6.0.91). Reads from ERCC 
(External RNA Controls Consortium, Ambion) spike-ins (included in SIRV Set3) were only used 
for QC purposes. For each sample, a linear model was fitted between log2 reads per million 
mapped reads (RPKM) values and log2 expected RNA amount of the ERCC transcripts to 
evaluate the accuracy of the RNA-seq measurement. Number of ERCC transcripts detected 
(transcripts per million > 0) and the corresponding R2 values from the linear models are listed in 
data file S2. Normalized gene counts (RPKM) were calculated with R package “edgeR” (version 
3.26.5) with “calcNormFactors” and “rpkm” functions. Only genes with RPKM > 1 in at least 12 
samples were used for downstream analyses. All samples were used in the model fitting and 
dispersion estimation steps. The Quasi-likelihood F-test method was then used to identify the 
differentially expressed genes between pairs of conditions of interest (FDR < 0.1). Heatmaps 
were generated with R package “pheatmap with colors representing row-scaled RPKM values. R 
package “fgsea’ was used for GSEA analysis. For each pair-wise comparison, genes are ranked 
based on their fold changes (NA vs. N or NM vs. N). GMT files for “C2: curated gene sets” and 
“C5: GO gene sets” were obtained from the MSigDB collections and used separately in the 
analysis. 
Small RNA-sequencing on epithelial cells  
To study changes in miRNA expression patterns in the same target cells, we further analyzed the 
Nitrofen and Nitrofen+rAFSC-EVs treated cells using small RNA-sequencing. Total RNA 
isolated from n=4 matched samples of Nitrofen and Nitrofen+rAFSC-EVs was used to prepare 
small RNA libraries (NEBNext small RNA kit) and subjected to miRNA-sequencing. 




single-end 50-base pair rapid run flowcell. FastQC was used to examine the quality of 
approximately 1.4 million mapped reads per sample. BBDuk (BBMap suite v37.90) was used to 
trim adaptor sequences from reads with reference adapter sequences provided by BBMap suite 
and settings “hdist=1 mink=11” for small RNA-seq reads. For miRNA size specificity, only 
reads less than 23 nucleotides in length were retained. Following trimming, FastQC was used to 
examine the quality of trimmed sequenced reads. miRDeep2 (v2.0.0) mapper.pl was used with 
default parameters to map reads of at least 18 nucleotides in length to rat genome (rnor6). 
Known and novel miRNAs were identified using miRDeep2 main algorithm (miRDeep2.pl) with 
default parameters and known mature miRNAs for rat which were obtained from miRBase 
(v22.1). Only known and novel miRNAs with reported miRDeep score ≥ 2 were retained for 
downstream analyses. 
Counts processing and differential miRNA expression analysis 
Prior to differential miRNA expression analysis, read counts were scaled to sample library sizes 
and read counts per million (CPM) were calculated using R (v3.6.0) edgeR functions “cpm” and 
“calcNormFactors” (v3.26.5). Only miRNAs with CPM ≥ 1 in at least 3 samples within each 
condition were retained for downstream analysis. Differentially expressed miRNAs were 
identified using edgeR. Quasi-likelihood F-test method was used to test for differential 
expression (FDR < 0.1) for rAFSC-EV-treated and nitrofen-injured lung epithelial cells (NA) 
compared to nitrofen-injured cells (N). 
miRNA-mRNA gene target correlation  
Rat orthologs of miRNA-mRNA gene targets were determined from TargetScan (v7.2) and 
miRTarBase (release v8.0). Only TargetScan gene targets with weighted context score percentile 




and logRPKM gene expression for a given pair. miRNA-gene pairs with Spearman’s correlation 
coefficient (rho) < 0 and p-value ≤ 0.05 were considered negatively correlated. 
Cargo-seq miRNA-mRNA interaction network 
miRNAs with a detected expression value ≥ 2 in rAFSC-EVs were considered in this analysis. 
miRNA-gene target pairs were determined as outlined above and shown as an interaction 
network generated using Cytoscape. Target genes that are differentially expressed (FDR < 0.1) 
and have lower expression in rAFSC-EV-treated samples (log2FC < 0) are shown in the 
interaction network (blue nodes). miRNAs detected in rAFSC-EVs with higher median logCPM 
expression in rAFSC-EV-treated and nitrofen-injured primary cells compared to nitrofen-injured 
untreated cells are considered “miRNA up in primary cells” (green nodes). “miRNA in rAFSC-
EV cargo” (white nodes) represent miRNAs detected in rAFSC-EV cargo and are not detected in 
rAFSC-EV-treated nitrofen-injured primary cells or these miRNAs have lower median logCPM 
expression in rAFSC-EV-treated nitrofen-injured primary cells compared to nitrofen-injured 









Fig. S1. Characterization of rAFSC-EVs and rMSC-EVs and effects on lung explants based 
on size and concentration. (A) Representative plot of the average size distribution of rAFSC-
EVs and rMSC-EVs visualized using nanoparticle tracking analysis. Data are representative of 
five 40-second videos of each EV preparation. X-axis = size distribution (nm), y-axis = 
concentration (particles/mL). (B) Representative transmission electron microscopy photos of 
rAFSC-EVs and rMSC-EVs; two different magnifications highlight the morphology of 
individual EVs at near fields (top) and far fields (bottom). Scale bar = 200 nm. (C) Expression of 
canonical EV markers TSG101, Flo-1, Hsp70, and CD63 obtained by Western blot analysis for 
rAFSC-EVs and rMSC-EVs in n=3 technical replicates. EV preparations do not express histone 
marker H3K27me3. (D) Representative plot of the average size distribution of medium/large 
rAFSC-EVs. Data are representative of five 40-second videos of each EV preparation. X-axis = 
size distribution (nm), y-axis = concentration (particles/mL). (E) Live cell tracking of RNA in 
medium/large rAFSC-EVs (m/l rAFSC-EVs), DAPI, blue. Scale bar = 100 µm. Cells were 
outlined based on light microscopy images to highlight the cell border. (F) Effects of EV size 
(small EVs, rAFSC-sEVs; medium/large, m/l rAFSC-EVs) on lung explant terminal bud count 
and mean surface area in Control (n=16), Nitrofen (n=17), Nitrofen+rAFSC-CM (n=12), 
Nitrofen+rAFSC-sEVs (n=12), and Nitrofen+rAFSC-m/lEVs (n=4). (G) Effects of decreasing 
doses of rAFSC-EVs (0.5%, 0.25%, 0.05% v/v) on lung explant terminal bud count and mean 
surface area in Control (n=16), Nitrofen (n=17), Nitrofen+0.5% v/v rAFSC-EVs (n=12), 
Nitrofen+0.25% v/v rAFSC-EVs (n=5), Nitrofen+0.05% v/v rAFSC-EVs (n=5). Groups were 
compared using Kruskal-Wallis (post-hoc Dunn’s nonparametric comparison) test for fig. S1 F 






Fig. S2. Effects of rAFSC-EVs on control lung explants and primary lung epithelial cells. 
(A and B) Addition of rAFSC-EVs on control lung explants quantified for terminal bud count, 
(A) and lung surface area, (B), in Control (n=16) and Control+rAFSC-EVs (n=4). Effects on 
control primary lung epithelial cells proliferation (C), and cell death rates (D) in Control (n=4) 
and Control+rAFSC-EVs (n=3), ns = P>0.05. Groups were compared using Mann-Whitney test 








Fig. S3. Effects of rMSC-EV administration on in vitro and ex vivo models of pulmonary 
hypoplasia. (A) Immunofluorescence co-stain experiment of proliferating cells and distal lung 
epithelium progenitor cells of lung explants (SOX9, green; EdU, pink, DAPI nuclear stain, blue; 
scale bar = 100 µm), quantified through number of EdU+ cell per DAPI and SOX9 fluorescence 
intensity (AU = arbitrary units) in n=4 biological replicates with a total of 50x50 µm fields 
covering entire lung sections as indicated: Control (n=157), Nitrofen (n=222), Nitrofen+rAFSC-
EVs (n=128), Nitrofen+rMSC-EVs (n=122). (B) Immunofluorescence experiment of surfactant 
protein C (SPC) expressing cells in lung explants (SPC, green; DAPI nuclear stain, blue; scale 
bar=100 µm), quantified by fluorescence intensity: Control (n=6), Nitrofen (n=4), 
Nitrofen+rAFSC-EVs (n=4), Nitrofen+rMSC-EVs (n=4). (C) TUNEL immunofluorescence 
experiments on lung explants grown for 72 h, quantified by TUNEL+ cells per DAPI in n=4 
biological replicates with a total of 50x50 µm fields covering entire lung sections as indicated: 
Control (n=311), Nitrofen (n=240), Nitrofen+rAFSC-EVs (n=107), Nitrofen+rMSC-EVs 
(n=191). (D) Proliferation rate of primary lung epithelial cells from control and nitrofen-injured 
hypoplastic lungs treated with medium only, rAFSC-EVs, or rMSC-EVs [5’EdU labeling 
Control (n=7), Nitrofen (n=5), Nitrofen+rAFSC-EVs (n=5), Nitrofen+rMSC-EVs (n=4)]. (E) 
Cell death rate of primary lung epithelial cells from control and nitrofen-injured hypoplastic 
lungs treated as in (D) (live/dead cytotoxicity assay in Control n=5, Nitrofen (n=5), 
Nitrofen+rAFSC-EVs (n=5), Nitrofen+rMSC-EVs (n=4). (F) Light microscopy photos of fetal 
rat lung organoids derived from nitrofen-injured hypoplastic lungs treated with rMSC-EVs. Scale 
bar = 100 µm. Representative photo of n=104 organoids imaged. (G) Proliferation of cells in 
organoids evaluated with immunofluorescence (Ki67 staining, green; scale bar = 50 µm) and 




(n=8), Nitrofen (n=7), Nitrofen+rAFSC-EVs (n=9), Nitrofen+rMSC-EVs (n=14). (H) SPC 
staining in organoids (green; DAPI nuclear stain, blue; scale bar = 50 µm) quantified with 
fluorescence intensity calculated from total corrected cellular fluorescence in Control (n=30), 
Nitrofen (n=31), Nitrofen+rAFSC-EVs (n=25), Nitrofen+rMSC-EVs (n=5). (I) CC10+ cells in 
organoids (green; DAPI nuclear stain, blue; scale bar = 50 µm) quantified with fluorescence 
intensity calculated from total corrected cellular fluorescence in Control (n=30), Nitrofen (n=30), 
Nitrofen+rAFSC-EVs (n=30), Nitrofen+rMSC-EVs (n=25). Groups were compared using 
Kruskal-Wallis (post-hoc Dunn’s nonparametric comparison) test for fig. S3 A-E, G-I, according 








Fig. S4. Analysis of protein and RNA cargo of rAFSC-EV and rMSC-EV. (A) Pathway 
enrichment analysis of rAFSC-EV enriched protein cargo in GO terms Biology Processes, 
Cellular Component, and Molecular Functions. (B) Effect of potential carry-over of RNase in 
rAFSC-EV-RNase experiments on control cell proliferation (n=17 technical replicates). The 
enzymatically treated rAFSC-EVs were separated from the supernatant, which was then 
administered to control lung epithelial cells (n=43 technical replicates). Groups were compared 
using unpaired t-test, according to Gaussian distribution assessed by D’Agostino Pearson 
omnibus normality test. (C) Heatmap showing expression levels of significantly different species 
of RNA (FDR<0.01) separated by type for cargo from rAFSC-EV (n=3) and rMSC-EV (n=2) 
samples. Rows and columns are displayed using hierarchical clustering (Ward’s method; row 
distance measure: Pearson correlation; column distance measure: Euclidean). Color scale 
represents rows scaled (scaled across samples for each gene), log2 transformed normalized 
counts. (D) Volcano plot of genes differentially expressed between nitrofen-injured lung 
epithelial cells and control (non-nitrofen exposed) lung epithelial cells. Each dot represents a 
gene with log2 fold change <-2 (lower expression in Nitrofen vs. Control, n=322 red nodes) or 






Fig. S5. Enrichment plots for RNA-seq analysis of rMSC-EV treated primary lung 
epithelial cells and effects on in vivo model of pulmonary hypoplasia. (A) Scatterplot of log 
fold changes between Nitrofen+rAFSC-EVs (NA) vs. Nitrofen (N) and Nitrofen+rMSC-EVs 
(NM) vs. N. Pearson correlation = 0.54 (p < 2.2e-16, 95% CI [0.53, 0.55]). Each dot represents a 
gene with its log fold change between NA vs. N shown on the X-axis and log fold change 
between NM vs. N shown on the Y-axis. Dots are colored based on if the gene is identified as 
significantly differentially expressed (FDR < 0.1) only in NA vs. N (red), in NM vs. N (blue), or 
in both comparisons (purple). See supplementary data file S3 for the full lists of differentially 
expressed genes. (B) Selected pathways identified with gene set enrichment analysis of NA vs. N 
and NM vs. N primary lung epithelial cells for GO pathways Biological Process, Cellular 
Component, and Molecular Function. See supplementary data file S4 for full lists of GSEA 
results. (C) GSEA enrichment plot of epithelial cell differentiation generated with all genes 
ranked by fold changes between Nitrofen vs. Nitrofen+rMSC-EV-treated. (D) Representative 
histology images (hematoxylin/eosin) of fetal lungs from fetal rabbits that underwent surgical 
CDH creation and were subjected to administration of rMSC-EVs prior to tracheal occlusion 
(CDH+TO+rMSC-EVs). Scale bar = 500 µm. (E and F) Differences in number of alveoli (radial 
alveolar count, E) and thickness of the alveolar wall (mean wall transection length, F) between 
CDH+TO+rAFSC-EVs (n=9) and CDH+TO+rMSC-EVs (n=8). Groups were compared using 
Mann-Whitney test for fig. S5 E and F, according to Gaussian distribution assessed by 






Fig. S6. Correlation analysis of miRNA-mRNA sequencing in primary lung epithelial cells. 
Negatively correlated miRNA-mRNA pairs in primary lung epithelial cells are graphed by log of 
counts per million mapped reads (CPM) of miRNA (purple) and mRNA (orange) for primary 
lung epithelial cells from Nitrofen (N) and Nitrofen+rAFSC-EVs (NA) conditions. For a given 
negatively correlated pair (n=3-4 replicates), logCPM expression is shown for miRNA (purple) 
and gene (orange). Expression is shown for nitrofen-injured lung epithelial cells (Nitrofen, N, 
circles) and rAFSC-EV-treated nitrofen-injured epithelial cells (Nitrofen+rAFSC-EVs, NA, 







Fig. S7. Effects of hAFSC-EVs and hMSC-EVs on human fetal lung epithelial cells and in 
the in vivo model of pulmonary hypoplasia. (A) Proliferation rate of primary human 
pulmonary alveolar epithelial cells (HPAEpiC) from a fetus at 21 weeks of gestation, injured 
with 400 µM of nitrofen exposure for 24 h, and then treated with medium only, or medium 
supplemented with 0.5% v/v GMP-grade hAFSC-EVs or hMSC-EVs. Replicates were conducted 
in n=4 technical replicates. (B) Number of viable cells per field for the same conditions as in (A). 
(C) hMSC-EVs labeled with PKH26 (red signal) entering HPAEpiC (live cells labeled with 
Calcein-AM, green, nucleus labeled with DAPI, blue). Scale bar = 25 µm. (D) Representative 
histology image (hematoxylin/eosin) of fetal lungs of rabbits that underwent surgical CDH 
creation and were administered hAFSC-EVs prior to tracheal occlusion (CDH+TO+hAFSC-
EVs). Scale bar = 500 µm. Samples are representative of Control (n=9), CDH (n=9), CDH+TO 
(n=9), CDH+TO+rAFSC-EVs (n=9), and CDH+TO+hAFSC-EVs (n=5). (E and F) Differences 
in number of alveoli (radial alveolar count, E) and thickness of the alveolar wall (mean wall 
transection length, F). Groups were compared using Kruskal-Wallis (post-hoc Dunn’s 
nonparametric comparison) test for fig. S7 E, F, according to Gaussian distribution assessed by 








Fig. S8. Influence of rAFSCs in co-culture with ex vivo and in vitro models of pulmonary 
hypoplasia and effects on rAFSC-EV miRNA cargo. (A and B) Effects on terminal bud count 
(A) and mean surface area (B) of nitrofen-injured fetal lung explants co-cultured with rAFSCs at 
72 h (n=7 biological replicates). (C and D) Proliferation rate (C) and cell death rate (D) of 
primary lung epithelial cells treated in co-culture with rAFSCs in transwells for 24 h (n=3 
biological replicates). (E) miRNA expression of rAFSCs compared with rAFSC-EVs through 
miRCURY LNA SYBR qPCR. Data are shown as normalized relative expression to rMSCs and 
rMSC-EVs for four members of the miR17~92 family (n=3 matched replicates per each 
condition). (F) Log of counts per million mapped reads (CPM) for the expression of miR17~92 
family members and paralogues in primary lung epithelial cells exposed to Nitrofen (N, n=4, 
grey triangles) and Nitrofen+rAFSC-EVs (NA, n=3, pink circles) identified through small RNA-
sequencing analysis. Groups were compared using Kruskal-Wallis (post-hoc Dunn’s 
nonparametric comparison) test for fig. S8 A and B, and with Mann-Whitney test for fig. S8 C 
and D, according to Gaussian distribution assessed by D’Agostino Pearson omnibus normality 
test. Groups in fig. S8 E were compared using Holm-Sidak method with alpha=5%, each target 
















p-value for fold change 
rAFSC / rMSC 
Anxa1 39 0.000 0.017 0.000 
Anxa11 54 0.000 0.001 0.122 
Anxa2 39 0.012 0.019 0.232 
Anxa3 36 0.000 0.001 0.374 
Anxa4 36 0.000 0.003 0.011 
Anxa5 36 0.000 0.012 0.000 
Anxa6 76 0.000 0.012 0.000 
Anxa7 50 0.000 0.002 0.000 
Cd63 26 0.000 0.001 0.001 
Celf1 52 0.000 0.000 0.374 
Hnrnpa1 34 0.000 0.001 0.157 
Hnrnpa2b1 32 0.000 0.001 0.118 
Hnrnpc 33 0.000 0.000 0.374 
Hnrnpf 46 0.000 0.001 0.001 
Hnrnph1 49 0.000 0.002 0.000 
Hnrnpk 51 0.000 0.001 0.028 
Hnrnpl 68 0.000 0.001 0.165 
Hnrnpm 74 0.000 0.001 0.036 
Hnrnpu 88 0.000 0.002 0.017 
Hnrnpul2 85 0.000 0.000 0.001 
Hspa1a 70 0.000 0.003 0.000 
Hspa2 70 0.000 0.001 0.374 
Hspa4 94 0.000 0.000 0.374 
Hspa5 72 0.008 0.010 0.032 
Hspa8 71 0.011 0.012 0.575 
Hspa9 74 0.000 0.002 0.000 
kDa: kilodaltons 
NSAF: normalized spectral abundance factor 
rAFSCs: rat amniotic fluid stem cells 




Table S2: miRNAs related to lung development that are differentially expressed in rAFSC-EVs over rMSC-EVs.  






rno-miR-17-5p chr15 103640915 103640937 + 59.87 22473.82 8.5522 0 
The mir 17-92 















- regulate embryonic 
growth, apoptosis, 
and fetal lung 
development (9); 
 
- regulate surfactant 
protein C secretion 
(miR19b and 92a) 
(70); 
 





rno-mir-17-2 chrX 140167738 140167815 - 59.87 22473.82 8.5522 0 
rno-mir-17-1 chr15 103640902 103640985 + 65.28 22863.5 8.4522 0 
rno-miR-17-1-3p chr15 103640952 103640973 + 0.71 177.19 7.958 0 
miR-18 
rno-miR-18a-5p chr15 103641054 103641076 + 3.07 953.84 8.2779 0 
rno-mir-18a chr15 103641038 103641133 + 5.28 1034.37 7.6146 0 
rno-miR-18a-3p chr15 103641095 103641115 + 2.2 81.58 5.2098 0 
miR-19 
rno-miR-19a-5p chr15 103641197 103641216 + 0 1.08 Inf 1 
rno-miR-19b-1-5p chr15 103641502 103641523 + 0 1.05 Inf 1 
rno-mir-19a chr15 103641185 103641266 + 2.71 1007.59 8.5407 0 
rno-miR-19a-3p chr15 103641233 103641255 + 2.71 1006.52 8.5392 0 
rno-mir-19b-2 chrX 140167226 140167321 - 16.7 5235.41 8.2922 0 
rno-miR-19b-3p chr15 103641540 103641562 + 16.7 5235.41 8.2922 0 
rno-mir-19b-1 chr15 103641487 103641573 + 16.7 5231.7 8.2912 0 
miR-20 
rno-miR-20a-3p chr15 103641408 103641428 + 0 1.6 Inf 0.8997 
rno-miR-20a-5p chr15 103641372 103641394 + 30.04 19844.96 9.3677 0 
rno-mir-20a chr15 103641357 103641441 + 30.04 19844.96 9.3677 0 
rno-miR-20b-5p chrX 140167407 140167429 - 0.51 21.61 5.3986 0.0038 
rno-mir-20b chrX 140167365 140167436 - 0.51 21.61 5.3986 0.0038 
miR-92 
rno-miR-92b-5p chr2 207955729 207955752 - 0.2 1.62 3.0149 1 
rno-miR-92a-1-5p chr15 103641619 103641641 + 2.2 15.58 2.8214 0.1041 
rno-mir-92a-1 chr15 103641609 103641686 + 1466.75 3152.85 1.104 0.0346 
rno-miR-92a-3p chr15 103641656 103641676 + 447.53 519.1 0.214 1 
rno-mir-92a-2 chrX 140167096 140167187 - 447.53 519.1 0.214 1 
rno-mir-92b chr2 207955680 207955762 - 404.68 109.76 -1.8824 0.1754 
rno-miR-92b-3p chr2 207955690 207955711 - 404.48 108.14 -1.9032 0.1696 
miR-106 
rno-miR-106b-5p chr12 21365432 21365452 - 12.55 2451.88 7.6103 0 
rno-mir-106b chr12 21365382 21365463 - 302.19 12390.58 5.3576 0 
rno-miR-106b-3p chr12 21365391 21365412 - 289.64 9939.25 5.1008 0 
miR-363 
rno-miR-363-3p chrX 140166956 140166976 - 3.21 3.72 0.2128 1 





rno-miR-93-5p chr12 21365223 21365245 - 953.63 108642.09 6.8319 0 
rno-mir-93 chr12 21365173 21365259 - 955.42 108717.23 6.8302 0 
rno-miR-93-3p chr12 21365185 21365207 - 1.79 75.15 5.3896 0 
miR-25 
rno-miR-25-3p chr12 21364981 21365002 - 5238.63 83820.36 4 0 
rno-mir-25 chr12 21364970 21365053 - 5262.06 83911.87 3.9952 0 
rno-miR-25-5p chr12 21365019 21365040 - 23.43 90.98 1.9574 0.0033 
miR-7 
rno-miR-7b chr9 9803964 9803986 - 0 66.56 Inf 0 
- miRNAs involved 
in surfactant protein 
C secretion and 
expressed in human 
ATI and/or ATII 
cells (70).  
rno-mir-7b chr9 9803905 9804014 - 0 66.56 Inf 0 
rno-miR-7a-2-3p chr1 141551398 141551419 + 0 2.68 Inf 0.6528 
rno-mir-7a-2 chr1 141551342 141551436 + 111.49 133696.6 10.2279 0 
rno-miR-7a-5p chr1 141551360 141551382 + 119.28 133897.01 10.1325 0 
rno-mir-7a-1 chr17 8879389 8879485 + 125.25 133996 10.0632 0 




rno-let-7f-1-3p chr17 18474397 18474417 + 0 37.3 Inf 4.00E-04 
rno-let-7f-1 chr17 18474334 18474422 + 
6660.8
5 188375.58 4.8218 0 
rno-let-7f-5p chr17 18474341 18474362 + 
7068.3
6 189106.28 4.7417 0 
rno-let-7f-2 chrX 21868509 21868591 - 
7072.7
1 189158.31 4.7412 0 
rno-let-7f-2-3p chrX 21868514 21868534 - 3.59 42.95 3.5827 0 
rno-mir-
219a-1 
rno-mir-219a-1 chr20 5895489 5895598 - 10.69 85.29 2.9963 0 
rno-miR-219a-1-
3p chr20 5895516 5895537 - 10.69 83.16 2.9598 0 
miR-103 
rno-mir-103-2 chr3 130329252 130329337 + 
3229.3
7 40889.34 3.6624 0 
rno-miR-103-3p chr10 20480402 20480424 + 
3229.3
7 40883.42 3.6622 0 
rno-mir-103-1 chr10 20480351 20480436 + 
3234.2








rno-mir-125b-1 chr8 44272846 44272932 + 
7718.5
9 19862 1.3636 0.0022 
mir-129-1 
rno-miR-129-1-3p chr4 56049143 56049161 + 0 2.66 Inf 0.5709 
rno-mir-129-1 chr4 56049095 56049166 + 369.44 5715.96 3.9516 0 
miR-542 
rno-miR-542-3p chrX 152777501 152777522 + 47.45 14042.5 8.2091 0 
rno-mir-542-1 chrX 152777453 152777531 + 60.06 14313.6 7.8968 0 
rno-mir-542-2 chrX 152784192 152784270 + 60.06 14313.6 7.8968 0 
rno-mir-542-3 chrX 153215172 153215250 + 60.06 14313.6 7.8968 0 
rno-miR-542-5p chrX 152777463 152777484 + 12.6 265.18 4.395 0 
miR-592 
rno-mir-592 chr4 54925353 54925448 - 18.39 4706.09 7.9992 0 
rno-miR-592 chr4 54925409 54925431 - 18.39 4705.01 7.9989 0 
miR-138 
rno-miR-138-5p chr19 11127530 11127552 - 5.59 109.53 4.2925 0 
-  miRNAs that 




different with sex 
and gestational age 
in E15-E18 lungs 
(72). 
rno-mir-138-1 chr8 130886768 130886866 + 5.85 109.53 4.2279 0 
rno-mir-138-2 chr19 11127479 11127560 - 6.87 124.48 4.1794 0 
rno-miR-138-2-3p chr19 11127485 11127505 - 1.28 19.31 3.9144 0.0039 
miR-182 
rno-miR-182 chr4 57221577 57221601 - 40.34 994.77 4.6241 0 
rno-mir-182 chr4 57221574 57221635 - 40.34 994.77 4.6241 0 
mir-296 
rno-miR-296-5p chr3 178408833 178408853 - 0.6 41.26 6.1007 0 
rno-mir-296 chr3 178408788 178408865 - 116.43 516.99 2.1507 0 




rno-miR-471-3p chrX 151267019 151267038 - 0 66.6 Inf 0 
- miRNAs involved 
in alveolarization 
and significantly 
changed in P10 or 




rno-mir-471 chrX 151267006 151267083 - 0.71 691.21 9.9218 0 
rno-miR-471-5p chrX 151267052 151267073 - 0.71 621.36 9.7681 0 
miR-455 rno-miR-455-5p chr5 83211466 83211487 + 120.43 1324.53 3.4593 0 
miR-322 
rno-miR-322-3p chrX 152773528 152773547 + 62.07 6528.84 6.7167 0 
rno-miR-322-5p chrX 152773490 152773511 + 11.56 2847.63 7.9448 0 
rno-mir-322-1 chrX 152773468 152773562 + 73.63 9392 6.995 0 
rno-mir-322-2 chrX 153211185 153211279 + 73.63 9392 6.995 0 
rno-miR-322-3p chrX 152773528 152773547 + 62.07 6528.84 6.7167 0 
miR-183 
rno-mir-183 chr4 57225370 57225479 - 13.24 316.45 4.5792 0 
rno-miR-183-5p chr4 57225432 57225453 - 13.24 315.9 4.5767 0 
miR-214 rno-miR-214-5p chr13 85024828 85024844 + 50.79 1468.47 4.8535 0 




rno-miR-130b-3p chr11 91182370 91182391 + 251.24 18538.82 6.2053 0 
rno-mir-130b chr11 91182320 91182401 + 254.57 18584.85 6.1899 0 
rno-mir-130a chr3 78661697 78661784 - 
1092.4
8 20003.91 4.1946 0 
rno-miR-130a-3p chr3 78661709 78661730 - 
1092.4
8 19991.05 4.1937 0 
rno-miR-130b-5p chr11 91182332 91182353 + 3.33 44.39 3.7371 0.09 
miR-463 
rno-miR-463-3p chrX 151270941 151270962 - 0 2165.36 Inf 0 
- miRNAs involved 
in the regulation of 
pluripotency and the 
reprogramming 
process in rats (73). 
rno-mir-463 chrX 151270931 151271008 - 0.26 3748.68 13.8374 0 
rno-miR-463-5p chrX 151270979 151270999 - 0.26 1582.78 12.5935 0 
miR-465 
rno-mir-465 chrX 151292178 151292254 - 0 2167.1 Inf 0 
rno-miR-465-5p chrX 151292223 151292244 - 0 2096.67 Inf 0 
rno-miR-465-3p chrX 151292189 151292210 - 0 68.81 Inf 0 
miR-471 
rno-miR-471-3p chrX 151267019 151267038 - 0 66.6 Inf  0 
rno-mir-471 chrX 151267006 151267083 - 0.71 691.21 9.9218  0 
rno-miR-471-5p chrX 151267052 151267073 - 0.71 621.36 9.7681  0 
miR-741 
rno-miR-741-3p chrX 151269275 151269296 - 0 816.46 Inf 0 
rno-mir-741 chrX 151269258 151269353 - 0 816.46 Inf 0 
miR-743b 
rno-mir-743b chrX 151248558 151248634 - 0 3809.35 Inf 0 
rno-miR-743b-5p chrX 151248603 151248624 - 0 2753.09 Inf 0 
rno-miR-743b-3p chrX 151248568 151248589 - 0 1054.16 Inf 0 
miR-871 
rno-mir-871 chrX 151282689 151282765 - 0 7147.82 Inf 0 
rno-miR-871-5p chrX 151282732 151282755 - 0 7109.67 Inf 0 
rno-miR-871-3p chrX 151282700 151282721 - 0 38.15 Inf 0 
miR-881 
rno-mir-881 chrX 151278812 151278888 - 0 2210.79 Inf 0 
rno-miR-881-3p chrX 151278823 151278844 - 0 1995.88 Inf 0 
rno-miR-881-5p chrX 151278860 151278878 - 0 214.9 Inf 0 
miR-883 
rno-mir-883 chrX 151255943 151256019 - 0 185.76 Inf 0 
rno-miR-883-3p chrX 151255953 151255974 - 0 175.6 Inf 0 
rno-miR-883-5p chrX 151255988 151256010 - 0 10.16 Inf 0.0072 
miR-3580 
rno-mir-3580 chrX 151290426 151290506 - 0 4306.44 Inf 0 
rno-miR-3580-3p chrX 151290438 151290459 - 0 4168.11 Inf 0 




miR: miRNA; rAFSCs: rat amniotic fluid stem cells; rMSCs: rat mesenchymal stem cells; chr: chromosome; inf: infinity; ATI: 








Table S3: miRNAs known to be involved in pulmonary hypoplasia and present in rAFSC-EVs. 











secondary to CDH 
(12, 74-76). 
rno-mir-200b chr5 176964166 176964260 - 4.65 0 Inf 0.4715 
rno-miR-200b-3p chr5 176964182 176964204 - 1.54 0 Inf 1 
rno-miR-200b-5p chr5 176964219 176964240 - 3.12 0 Inf 0.7365 
rno-miR-200c-5p chr4 224254426 224254446 - 0 0.55 Inf 1 
rno-mir-200c chr4 224254382 224254450 - 12.7 65.95 2.376 0.0014 
rno-miR-200c-3p chr4 224254386 224254406 - 12.7 65.95 2.376 0.0014 
rno-miR-200a-3p chr5 176963402 176963423 - 5.57 3.8 -0.5508 1 
rno-mir-200a chr5 176963388 176963476 - 6.08 3.8 -0.6778 1 
miR-10 
rno-miR-10b-3p chr3 68113726 68113746 + 27.86 172.28 2.6286 1.00E-04 
rno-mir-10b chr3 68113662 68113770 + 29928.19 88517.54 1.5645 4.00E-04 
rno-miR-10b-5p chr3 68113689 68113710 + 29900.33 88350.61 1.5631 4.00E-04 
rno-miR-10a-3p chr10 83968744 83968765 + 4.78 2.66 -0.8426 1 
rno-mir-10a chr10 83968682 83968791 + 727.64 88.91 -3.0328 0.0256 
rno-miR-10a-5p chr10 83968703 83968725 + 722.86 86.25 -3.0671 0.0232 







  rno-mir-33 chr7 123415303 123415371 + 3.94 49.49 3.6504 0 
  rno-miR-33-5p chr7 123415308 123415328 + 2.43 33.88 3.8032 2.00E-04 
miR-193 rno-mir-193b chr14 30144277 30144359 - 43.73 552.81 3.66 0 
  rno-miR-193b-3p chr14 30144291 30144309 - 2.88 543.63 7.5585 0 
  rno-miR-193a-3p chr10 64583983 64584004 - 2.32 22.62 3.2878 0.0117 
  rno-mir-193a chr10 64583972 64584057 - 60.8 160.84 1.4034 0.0185 
  rno-miR-193a-5p chr10 64584017 64584038 - 56.55 138.22 1.2894 0.0417 
  rno-miR-193b-5p chr14 30144328 30144345 - 40.85 6.45 -2.6624 0.1982 
miR-338 rno-mir-338 chr10 108793410 108793475 - 0 16.14 Inf 2.00E-04 
  rno-miR-338-3p chr10 108793413 108793435 - 0 8.1 Inf 0.0761 
  rno-miR-338-5p chr10 108793449 108793470 - 0 8.04 Inf 0.0266 
 rno-mir-30a chr9 28377823 28377893 + 6702.06 91515.55 3.7713 0  
 rno-miR-30a-5p chr9 28377828 28377849 + 6239.92 88950.46 3.8334 0  











miR-30c rno-mir-30c-2 chr9 28397564 28397647 + 126.18 1532.57 3.6024 0 
  rno-mir-30c-1 chr5 143494757 143494845 - 113.57 1523.39 3.7457 0 
  rno-miR-30c-5p chr5 143494807 143494829 - 110.28 1483.2 3.7494 0 
  rno-miR-30c-1-3p chr5 143494769 143494790 - 3.28 40.71 3.6316 1.00E-04 
  rno-miR-30c-2-3p chr9 28397617 28397638 + 15.9 49.37 1.6346 0.0871 
miR-22 rno-miR-22-3p chr10 62013698 62013719 + 11519.53 80600.86 2.8067 0 
  rno-miR-22-5p chr10 62013660 62013681 + 43.31 499.36 3.5272 0 
  rno-mir-22 chr10 62013642 62013736 + 11562.84 81100.22 2.8102 0 
miR-532 rno-mir-532 chrX 16894994 16895072 + 9.75 128.96 3.7249 0 
  rno-miR-532-5p chrX 16895004 16895025 + 3.92 94.01 4.5842 0 
  rno-miR-532-3p chrX 16895041 16895062 + 5.83 34.95 2.5827 0.013 
miR-28 rno-miR-28-3p chr11 81345228 81345249 + 1115.34 34443.35 4.9487 0 
  rno-miR-28-5p chr11 81345188 81345209 + 76.11 3651.38 5.5842 0 
  rno-mir-28 chr11 81345175 81345260 + 1191.45 38095.82 4.9988 0 
miR-362 rno-mir-362 chrX 16902294 16902358 + 0 115.82 Inf 0 
  rno-miR-362-3p chrX 16902335 16902356 + 0 114.72 Inf 0 
  rno-miR-362-5p chrX 16902298 16902321 + 0 1.09 Inf 1 
miR-3559 rno-mir-3559 chrX 76261608 76261722 - 26.31 1132.64 5.4279 0 
  rno-miR-3559-3p chrX 76261633 76261654 - 21.44 712.18 5.0536 0 




Table S4: Genes differentially expressed in nitrofen-injured lung epithelial cells  
Gene Name Link to lung development or epithelial homeostasis Ref. 
Down-regulated 
Nkx2.1 NK2 Homeobox 1  Essential regulator of lung development and a marker of 
early lung epithelial progenitor 
(77) 
 
Hipk2 Homeodomain Interacting 
Protein Kinase 2 
NKX2-1 binding partner (78) 
 
Alcam Activated Leukocyte Cell 
Adhesion Molecule 
Marker of type II alveolar epithelial cells (79) 
 
Mxd4 MAX Dimerization 
Protein 4 
Highly prioritized gene in neonates with pulmonary 
hypoplasia /CDH  
(80) 
 




Fgfr3 Fibroblast Growth Factor 
Receptor 3 
Upregulation of FGFR3 disrupts alveologenesis in 
experimental and human pulmonary hypoplasia/CDH.  
(80, 82) 
 
Sult1a1 Sulfotransferase Family 
1A Member 1 
Upregulated in hypoxic lung injury, and required for 
nitrofen activation and mutagenicity 
(83, 84) 
 
Dusp1 Dual Specificity 
Phosphatase 1 
Negatively regulates autophagy, a process required for 
fetal lung branching morphogenesis 
(85, 86) 
 
Sqstm1 Sequestosome 1 Marker of autophagy impairment increased in stressed 
conditions 
(86, 87)  
Ncao4 Nuclear Receptor 
Coactivator 4 
Involved in ferritin turnover and autophagy regulation (88) 
 
Herpud1 Homocysteine Inducible 
ER Protein With Ubiquitin 
Like Domain 1 
Involved in ER stress response, a critical process for 
tissue homeostasis that is dysregulated in pulmonary 
hypoplasia 
(40, 89) 




Inhibitor 1C  
Fuca2 Alpha-L-Fucosidase 2 Involved in repair of damaged lung epithelial cells (91) 
 
Clic3 Chloride Intracellular 
Channel 3 
Activator of MAPK signaling, a pathway that is 
upregulated in nitrofen-injured lung epithelial cells 
(61, 92)  
Sesn1 Sestrin 1 Repressor of PDGFRβ signaling, a pathway that is 
dysregulated in nitrofen lungs 
(93) 
 
Flcn Folliculin Involved in EGFR signaling, a pathway that is down-




Flna Filamin A Actin-binding protein involved in ciliogenesis, FLNA 
mutations are associated with severe diffuse lung disease 
and alveolar simplification 
(96, 97) 
 
Pdlim5 PDZ And LIM Domain 5 Scaffolding protein that is required for TGF-β/Smad 
signaling in alveolar epithelial cells, and that prevents 
hypoxia-induced pulmonary hypertension 
(98) 
 




Igf1r Insulin Like Growth 
Factor 1 Receptor 
Involved in epithelial proliferation and differentiation, 
(downregulated in nitrofen) 
(32) 
 
Gnaq G Protein Subunit Alpha 
Q 
Nucleotide-binding protein expressed in alveolar Type II 
epithelial cells that controls surfactant homeostasis 
(100) 
 
Myh9l1 Myosin Heavy Chain 9 
non-muscle-like 1 




Clic1 Chloride Intracellular 
Channel 1 
Mitochondria and ER chloride channel protein that 
regulates redox balance and ER stress 
(40, 102) 
 




Nuclear Import Factor 
Hikeshi 
function of the secretory apparatus in club cells   
Cxcl2 C-X-C Motif Chemokine 
Ligand 2 








Table S5: Inter-species conservation of top enriched miRNA in hAFSC-EVs 
 
Human miRNA Rabbit miRNA orthologue Sequence 
hsa-let-7b-5p  ocu-let-7b 5`-UGAGGUAGUAGGUUGUGUGGUU-3` 
 
hsa-miR-23a-3p ocu-miR-23b-3p 5`-AUCACAUUGCCAGGGAUUUCC-3` 
 


































hsa-miR-145-5p  ocu-miR-145-5p 5`-GUCCAGUUUUCCCAGGAAUCCCU-3` 
 
hsa-miR-320c  ocu-miR-197-3p 5`-AAAAGCUGGGUUGAGAGGGU-3` 
 








Table S6: Primer sequences used in this study 
 
Target Primer sequence 
rat Gapdh-F 5`-GGGTGTGAACCACGAGAAAT-3` 
rat Gapdh-R 5`-ACTGTGGTCATGAGCCCTTC-3` 
rat Fgf10-F 5`-CCACATACATTTGCCTGCCG-3` 
rat Fgf10-R 5`-GGGGAAACTCTATGGCTCAAAAG-3` 
rat Vegfa-F 5`-AGAAAGCCCATGAAGTGGTGA-3` 
rat Vegfa -R  5`-TCTCATCGGGGTACTCCTGG-3` 
rat Flt1-F 5`-GTACCTCACCGTGCAAGGAA-3` 
rat Flt1-R 5`-TTCGGAAGAAGACCGCTTCA-3` 
rat Kdr-F 5`-CTGCAGGACCAAGGCAACTA-3` 
rat Kdr-R 5`-CATGCGCTCTAGGATGACGA-3` 
rabbit RPLP0-F 5`-CTGTGCCAGCTCAGAACACT-3` 
rabbit RPLP0-R 5`-TGCACGTCGCTCAGGATTTC-3` 
rabbit PLIN-2-F 5`-TGCTGAGCACATCGAGTCAC-3` 
rabbit PLIN-2-R 5`-ATGTTGGACAGGAGGCTGTG-3` 
rabbit BMP2-F 5`-GGAAGCTTTGGGAGACGACA-3` 
rabbit BMP2-R 5`-TTTCGAGTTGGCTGTTGCAG-3` 
rabbit BMP4-F 5`-CTTCCACCACGAAGAACATCTG-3` 
rabbit BMP4-R 5`-ATGGCCTCGTTCTCTGGGAT-3` 
rabbit Id1-F 5`-TTCTACAACCGTCTCCTGCG-3` 




Table S7: Details of antibodies used in this study 
 
Target Antibody Company Lung explants Organoids  Primary epithelial 
cells 
 
1° 2° 1° 2° 1° 2° 
SPC ab40879 Abcam 
(Cambridge, 
UK) 
1:500 1:1,000 1:200 1:1,000 1:200 1:1,000 
SOX9 HPA001758 SigmaAldrich 
(St Louis, MO) 
1:500 1:1,000 - - - - 
Ki67 ab15580 Abcam 
(Cambridge, 
UK) 
- - 1:100 1:1,000 - - 
CC10 sc-365992 SantaCruz 
Biotechnology 
(Dallas, TX) 
- - 1:50 1:1,000 - - 
Vimentin ab92547 Abcam 
(Cambridge, 
UK) 
- - - - 1:100 1:1,000 
 














EM-grade 10nm gold 
tag 
Electron Microscopy 
Sciences, Hatfield, PA 
- - - 1:25 
RNase PA578151 Thermofisher Scientific, 
Waltham, Massachusetts 





EM-grade 25nm gold 
tag 
Electron Microscopy 
Sciences, Hatfield, PA 
- - - 1:25 




1:10,000 - - 
Flo-1 610820 BD Transduction 
Laboratories, San Jose, CA 
1:1,000 
 
1:3,000 - - 




1:10,000 - - 
SPC: surfactant protein C, 
SOX 
9: SRY-Box 9, 
Ki67: marker of proliferation Ki67, 
CC10: Clara Cells 10 KDa Secretory Protein, 




Flo-1: Flotillin 1, 
Hsp70: Heat Shock Protein 70 
 
 
